<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">55829</article-id><article-id pub-id-type="doi">10.7554/eLife.55829</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>RAB23 coordinates early osteogenesis by repressing FGF10-pERK1/2 and GLI1</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-174434"><name><surname>Hasan</surname><given-names>Md Rakibul</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5477-6934</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-174558"><name><surname>Takatalo</surname><given-names>Maarit</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-174559"><name><surname>Ma</surname><given-names>Hongqiang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-174560"><name><surname>Rice</surname><given-names>Ritva</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-109364"><name><surname>Mustonen</surname><given-names>Tuija</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2429-5064</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-91851"><name><surname>Rice</surname><given-names>David PC</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9301-3078</contrib-id><email>david.rice@helsinki.fi</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Craniofacial Development and Malformations research group, Orthodontics, Oral and Maxillofacial Diseases, University of Helsinki</institution><addr-line><named-content content-type="city">Helsinki</named-content></addr-line><country>Finland</country></aff><aff id="aff2"><label>2</label><institution>Oral and Maxillofacial Diseases, Helsinki University Hospital</institution><addr-line><named-content content-type="city">Helsinki</named-content></addr-line><country>Finland</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Reviewing Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rosen</surname><given-names>Clifford J</given-names></name><role>Senior Editor</role><aff><institution>Maine Medical Center Research Institute</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>14</day><month>07</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e55829</elocation-id><history><date date-type="received" iso-8601-date="2020-02-06"><day>06</day><month>02</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-07-13"><day>13</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Hasan et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Hasan et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-55829-v2.pdf"/><abstract><p>Mutations in the gene encoding <italic>Ras-associated binding protein 23</italic> (<italic>RAB23</italic>) cause Carpenter Syndrome, which is characterized by multiple developmental abnormalities including polysyndactyly and defects in skull morphogenesis. To understand how RAB23 regulates skull development, we generated <italic>Rab23-</italic>deficient mice that survive to an age where skeletal development can be studied. Along with polysyndactyly, these mice exhibit premature fusion of multiple sutures resultant from aberrant osteoprogenitor proliferation and elevated osteogenesis in the suture. FGF10-driven FGFR1 signaling is elevated in <italic>Rab23<sup>-/-</sup></italic>sutures with a consequent imbalance in MAPK, Hedgehog signaling and RUNX2 expression. Inhibition of elevated pERK1/2 signaling results in the normalization of osteoprogenitor proliferation with a concomitant reduction of osteogenic gene expression, and prevention of craniosynostosis. Our results suggest a novel role for RAB23 as an upstream negative regulator of both FGFR and canonical Hh-GLI1 signaling, and additionally in the non-canonical regulation of GLI1 through pERK1/2.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>In many animals, the skull is made of several separate bones that are loosely joined during childhood and only fuse into one piece when the animal stops growing. A genetic disease called Carpenter syndrome causes the bones of the skull to fuse early in life, stopping it from growing correctly. Carpenter syndrome is often caused by changes to the gene responsible for making a protein called RAB23.</p><p>RAB23 helps move other molecules and cell components between different parts of the cell, and is therefore involved in a number of cellular processes. Previous studies suggest that RAB23 has a role in many parts of the body during development. Yet, it is unclear which cells in the skull depend on RAB23 activity and how this protein is controlled.</p><p>To answer this question, Hasan et al. grew pieces of developing skull bones that had been taken from mice lacking the RAB23 protein in the laboratory. Examining these samples revealed that RAB23 is active in cells called osteoblasts that add new bone to the edge of each piece of the skull as it grows. Hasan et al. also found that RAB23 regulates two cellular signaling pathways – called the hedgehog pathway and the fibroblast growth factor pathway – that interact with one another and co-ordinate skull development.</p><p>These findings show how RAB23 controls the growth and fusion of skull bones in developing animals. This could improve our understanding of the role RAB23 plays in other processes during development. It also sheds light on the mechanisms of Carpenter syndrome which may inform new approaches for treating patients.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>RAB23</kwd><kwd>Craniosynostosis</kwd><kwd>MAPK signaling</kwd><kwd>GLI1</kwd><kwd>RUNX2</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002341</institution-id><institution>Suomen Akatemia</institution></institution-wrap></funding-source><award-id>257472</award-id><principal-award-recipient><name><surname>Rice</surname><given-names>David PC</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006306</institution-id><institution>Sigrid Juséliuksen Säätiö</institution></institution-wrap></funding-source><award-id>4702957</award-id><principal-award-recipient><name><surname>Rice</surname><given-names>David PC</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Helsinki University Hospital Research Foundation</institution></institution-wrap></funding-source><award-id>TYH2019250</award-id><principal-award-recipient><name><surname>Rice</surname><given-names>David PC</given-names></name></principal-award-recipient></award-group><funding-statement>The funders supported to perform this research.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>RAB23 regulates calvarial bone and suture development both independently through, and by cross-talk between, Hedgehog and fibroblast growth factor signaling.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Ras-associated binding protein 23 (RAB23) belongs to the RAB family of small GTPases, which function during several steps in cell vesicle trafficking (<xref ref-type="bibr" rid="bib11">Evans et al., 2003</xref>). RAB23 has 35–40% sequence homology with other RABs, it localizes to the plasma membrane and is proposed to regulate cargo internalization and relocation in the cell (<xref ref-type="bibr" rid="bib11">Evans et al., 2003</xref>; <xref ref-type="bibr" rid="bib33">Leaf and Von Zastrow, 2015</xref>; <xref ref-type="bibr" rid="bib38">Lim and Tang, 2015</xref>; <xref ref-type="bibr" rid="bib45">Olkkonen et al., 1994</xref>). RAB23 is unusual amongst RABs as it is involved in embryogenesis, for instance in heart and limb patterning, neural tube closure and skeletal development (<xref ref-type="bibr" rid="bib10">Eggenschwiler and Anderson, 2000</xref>; <xref ref-type="bibr" rid="bib8">Eggenschwiler et al., 2001</xref>; <xref ref-type="bibr" rid="bib13">Fuller et al., 2014</xref>; <xref ref-type="bibr" rid="bib16">Günther et al., 1994</xref>; <xref ref-type="bibr" rid="bib19">Hor and Goh, 2018</xref>). RAB23 negatively regulates Hh signaling during mouse neural tube development (<xref ref-type="bibr" rid="bib10">Eggenschwiler and Anderson, 2000</xref>), and it controls nodal signaling independently of Hh signaling during vertebrate left-right patterning (<xref ref-type="bibr" rid="bib13">Fuller et al., 2014</xref>). RAB23 is involved in trafficking D1-type dopaminergic receptors (<xref ref-type="bibr" rid="bib33">Leaf and Von Zastrow, 2015</xref>) and kinesin-2 motor protein Kif-17 (<xref ref-type="bibr" rid="bib38">Lim and Tang, 2015</xref>) to the primary cilium. However, direct ciliary function of RAB23 is unclear as cilium length and function are reported normal in <italic>Rab23<sup>-/-</sup></italic> mice (<xref ref-type="bibr" rid="bib11">Evans et al., 2003</xref>; <xref ref-type="bibr" rid="bib13">Fuller et al., 2014</xref>).</p><p>Multiple mutations in <italic>RAB23</italic> have been reported in patients with the autosomal recessive Carpenter syndrome; the majority of mutations result in nonsense-mediated decay while others include missense and in-frame deletions (<xref ref-type="bibr" rid="bib24">Jenkins et al., 2011</xref>). Carpenter syndrome (CS, MIM #201000) or Acrocephalopolysyndactyly type II is a multi-organ developmental disorder with polysyndactyly, congenital heart defects, mental retardation, obesity and craniosynostosis as central features (<xref ref-type="bibr" rid="bib4">Carpenter, 1909</xref>; <xref ref-type="bibr" rid="bib23">Jenkins et al., 2007</xref>).</p><p>Craniosynostosis is the premature fusion of one or more craniofacial sutures that results in major disruption of face and skull growth. Mesenchymal cells in the center of the suture must be kept in an undifferentiated state to maintain suture patency, while progenitor cells at the osteogenic fronts proliferate and differentiate to facilitate bone growth. Suture biogenesis is dependent on the correct patterning of the skeletal elements, as well as the regulation of the mesenchymal stem cell niche, osteogenic condensation formation, osteoprogenitor proliferation and differentiation (<xref ref-type="bibr" rid="bib55">Rice and Rice, 2008</xref>; <xref ref-type="bibr" rid="bib63">Twigg and Wilkie, 2015</xref>). These developmental processes are regulated to permit coordinated craniofacial growth, without the fusion of the neighboring bones and consequent cessation of growth.</p><p>Mutations in <italic>FGFR</italic>s are a major cause of syndromic craniosynostosis, with many of the mutations conferring a gain of function (<xref ref-type="bibr" rid="bib17">Hajihosseini, 2008</xref>; <xref ref-type="bibr" rid="bib71">Wilkie et al., 2017</xref>). FGFRs isoforms show a distinct FGF ligand binding affinity and biological functions (<xref ref-type="bibr" rid="bib46">Ornitz and Itoh, 2015</xref>). However, studies have shown that in an Apert syndrome (<italic>FGFR2</italic> mutation) mouse model isoform FGFR2c loses ligand specificity, and is able to bind with cognate FGF10 (<xref ref-type="bibr" rid="bib21">Ibrahimi et al., 2001</xref>; <xref ref-type="bibr" rid="bib22">Ibrahimi et al., 2004</xref>; <xref ref-type="bibr" rid="bib25">Johnson and Wilkie, 2011</xref>; <xref ref-type="bibr" rid="bib73">Yu et al., 2000</xref>). Interestingly, genetic knockdown of <italic>Fgf10</italic> in this mouse model could rescue the premature fusion (<xref ref-type="bibr" rid="bib18">Hajihosseini et al., 2009</xref>). FGF signaling pathway members have not been linked to RAB23-mediated trafficking. However, study suggests that RAB23 resides in the plasma membrane and proposed to be involved in endocytosis (<xref ref-type="bibr" rid="bib11">Evans et al., 2003</xref>). In this context, RAB23 might have a direct role in growth factor receptor recycling and turnover, and therefore regulate the availability of the FGF receptors at the cell surface (<xref ref-type="bibr" rid="bib32">Langemeyer et al., 2018</xref>; <xref ref-type="bibr" rid="bib74">Zerial and McBride, 2001</xref>).</p><p>Similar to Carpenter syndrome, several craniosynostosis syndromes caused by mutations in <italic>FGFRs</italic> are characterized by patients exhibiting syndactyly and occasionally polysyndactyly (<xref ref-type="bibr" rid="bib15">Goos and Mathijssen, 2019</xref>; <xref ref-type="bibr" rid="bib41">Mantilla-Capacho et al., 2005</xref>). Also, mutations in several hedgehog (Hh) pathway members cause polydactyly (<xref ref-type="bibr" rid="bib40">Malik, 2014</xref>; <xref ref-type="bibr" rid="bib64">Ullah et al., 2019</xref>). Notably, Greig cephalopolysyndactyly syndrome (MIM <bold>#</bold> 175700) is caused by haploinsufficiency of the Hh signaling negative regulator, <italic>GLI3</italic> (<xref ref-type="bibr" rid="bib68">Vortkamp et al., 1991</xref>). In addition to the polysyndactyly, some patients with Greig cephalopolysyndactyly syndrome exhibit craniosynostosis, and the mouse model for Greig cephalopolysyndactyly syndrome (<italic>Gli3<sup>Xt-J/Xt-J</sup></italic>) shows complete phenotypic penetrance for both craniosynostosis and polydactyly (<xref ref-type="bibr" rid="bib20">Hurst et al., 2011</xref>; <xref ref-type="bibr" rid="bib54">Rice et al., 2010</xref>). Also, a recurrent mosaic mutation in the hedgehog receptor <italic>Smoothened</italic> (<italic>SMO</italic>) causes craniosynostosis and polysyndactyly (<xref ref-type="bibr" rid="bib62">Twigg et al., 2016</xref>). These overlapping skeletal phenotypes caused by mutations in <italic>FGFR</italic>s, Hh regulators and <italic>RAB23</italic> are suggestive of common etiological mechanisms. FGF and Hh signaling have well-defined roles during intramembranous osteogenesis. FGF signaling regulates many stages including mesenchymal condensation formation, osteoprogenitor proliferation and differentiation and activation of the osteogenic transcription factor RUNX2 (<xref ref-type="bibr" rid="bib7">Debiais et al., 1998</xref>; <xref ref-type="bibr" rid="bib28">Kim et al., 1998</xref>; <xref ref-type="bibr" rid="bib46">Ornitz and Itoh, 2015</xref>; <xref ref-type="bibr" rid="bib72">Yoon et al., 2014</xref>). IHH positively regulates osteoprogenitor recruitment to the osteogenic front and GLI transcription factors regulate stem cell maintenance and osteoprogenitor proliferation (<xref ref-type="bibr" rid="bib37">Lenton et al., 2011</xref>; <xref ref-type="bibr" rid="bib54">Rice et al., 2010</xref>; <xref ref-type="bibr" rid="bib66">Veistinen et al., 2012</xref>; <xref ref-type="bibr" rid="bib75">Zhao et al., 2015</xref>). Interestingly, RAB23 regulates GLI1 in a Su(Fu)-dependent manner (<xref ref-type="bibr" rid="bib5">Chi et al., 2012</xref>) and GLI1-positive cells have been identified in the suture as the main source of mesenchymal stem cells that plays crucial role in suture patency (<xref ref-type="bibr" rid="bib75">Zhao et al., 2015</xref>).</p><p>The aim of this study was to determine the role of RAB23 during intramembranous bone development. Previously, it has not been possible to study skeletal development in RAB23 deficient mice due to their early lethality. Here, we generated RAB23 deficient (<italic>Rab23<sup>-/-</sup></italic>) mice that survived until embryonic day (E) 18.5, and this allowed us to investigate how RAB23 regulates bone formation. Similar to Carpenter syndrome patients, RAB23 deficient mice exhibited polysyndactyly and multiple craniosynostoses. We show that disruption of <italic>Rab23</italic> leads to an upregulation of <italic>Pitx2</italic>, <italic>Fgf10</italic> and <italic>Fgfr1b</italic> expression, decreased p38 and enhanced pERK1/2-RUNX2 signaling along with elevated osteoprogenitor proliferation. In addition, <italic>Hh</italic> signaling was amplified with increased expression of GLI1. During in vitro culture, inhibition of elevated pERK1/2 normalized osteoprogenitor proliferation, corrected the aberrant GLI1 and RUNX2 expressions, and rescued the lambdoid suture fusion. Our results suggest a novel role for RAB23 as an upstream regulator of both FGF10-pERK1/2 and Hh-GLI1, and the additional regulation of GLI1 by pERK1/2, to coordinate the initiation of osteogenesis.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>Rab23<sup>-/-</sup></italic> mice exhibit craniosynostosis in multiple sutures</title><p><italic>Rab23 open brain 2 (opb2)</italic> homozygous mutant mice did not produce RAB23 protein in primary cells, analyzed by western blot (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) and will therefore be referred to as <italic>Rab23<sup>-/-</sup></italic> mice. <italic>Rab23<sup>-/-</sup></italic> C3 Heb/FeJ mice, generated through an ENU screen, survive until E12.5 rendering full analysis of organogenesis impossible (<xref ref-type="bibr" rid="bib8">Eggenschwiler et al., 2001</xref>; <xref ref-type="bibr" rid="bib27">Kasarskis et al., 1998</xref>). To obviate the gestation lethality before skeletal development, we backcrossed <italic>Rab23<sup>-/-</sup></italic> C3 Heb/FeJ mice onto the C57Bl/6 strain. After six generations, the survival of the <italic>Rab23<sup>-/-</sup></italic> homozygote embryos were prolonged to E18.5, and this allowed us to study skeletal development of these mice.</p><p><italic>Rab23<sup>-/-</sup></italic> mice at embryonic day E18.5 exhibited craniosynostosis in the coronal, parietal-temporal, fronto-nasal and in the lambdoid sutures when compared to their wild type (Wt) littermates (<xref ref-type="fig" rid="fig1">Figure 1A–E</xref>). The prevalence of premature suture fusion in <italic>Rab23<sup>-/-</sup></italic> mice represented as percentage and only parieto-temporal sutures showed bi-lateral suture fusion (100%) in all the samples (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Along with craniosynostosis, <italic>Rab23<sup>-/-</sup></italic> mice showed skeletal patterning defects in the forelimbs and hindlimbs. <italic>Rab23<sup>-/-</sup></italic> mice showed pre-axial polydactyly (seven digits) of the forelimb and preaxial polysyndactyly (seven digits) of the hindlimbs (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Polydactyly and craniosynostosis were observed (100%) in all <italic>Rab23<sup>-/-</sup></italic> samples examined.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Deficiency of RAB23 causes premature fusion of multiple sutures and polysyndactyly.</title><p>(<bold>A–E</bold>) Analysis of Wt and <italic>Rab23<sup>-/-</sup></italic> skulls by µ-CT (<bold>A–C</bold>) and alizarin red, alcian blue staining (<bold>D–E</bold>) at E18.5. <italic>Rab23<sup>-/-</sup></italic> skulls show fusion in the parieto-temporal suture (B-a, black arrow), coronal suture (B-a, green arrow and B-b, µ-CT slice, green arrow), frontonasal suture (C-a, arrow) and lambdoid suture (E-a, arrow). Wt sutures were open at this embryonic stage (<bold>A–a, A–b</bold>) (<italic>n</italic> = 10 for each age and genotype). fb: frontal bone, pb: parietal bone. Scale bar: 1 mm. (<bold>F</bold>) The prevalence of suture fusion in <italic>Rab23<sup>-/-</sup></italic> mouse at E18.5 shown in percentage. Only parieto-temporal suture showed bi-lateral suture fusion in all the samples. (<italic>n</italic> = 10 for sagittal and interfrontal suture, n = 40 for lambdoid suture and n = 20 for other sutures). (<bold>G</bold>) Skeletal Analysis of the limbs in <italic>Rab23<sup>-/-</sup></italic> mouse show pre-axial polydactyly of the fore limb (FL, 1a, 2a) and pre axial polysyndactyly of the hind limb (HL, 1a, 2a) at E18.5 (n = 10 for each age and genotype. Scale bar: 1.5 mm. (<bold>H–K</bold>) E18.5 mouse calvaria indicating fb: frontal bone, pb: parietal bone, ipb: interparietal bone and ls: lambdoid suture (<bold>H</bold>). Analysis of Wt and <italic>Rab23<sup>-/-</sup></italic> calvaria by µ-CT at E18.5 shows <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures form bony protrusions from parietal bones project towards the interparietal bones (J, arrow), or ectopic bony islands in the mid-sutural mesenchyme (K, arrow) (n = 6 for each age and genotype). Scale bar: 500 µm. (<bold>L</bold>) Measurements of the lambdoid suture shows <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures are narrower as compare to the Wt samples at E18.5 (n = 6 for each age and genotype). Data represented as mean ± SD, paired Student’s <italic>t</italic>-test was used. Statistical significance was defined as a p<italic>-value &lt; </italic>0.05 (*). (<bold>M</bold>) In vitro calvaria culture system. This system was used to culture Wt and <italic>Rab23<sup>-/-</sup></italic> calvaria containing patent lambdoid sutures at E17.5 and E18.5. (<bold>N, O</bold>) Represents E18.5 Wt and patent lambdoid suture containing <italic>Rab23<sup>-/-</sup></italic> calvaria culture in vitro for 3 days in presence of alizarin red. <italic>Rab23<sup>-/-</sup></italic> lambdoid suture shows fusion at day 3 (N, alizarin red bone staining, O, µ-CT images), whereas Wt controls remain open (n = 10 for each genotype). Scale bar: 500 µm. (<bold>P</bold>) <italic>Rab23</italic> expression in the whole calvarial tissue at E16.5 is shown by digoxigenin labeled whole mount in situ hybridization (<bold>P–a</bold>) and shown at E15.5 sutural tissue sections by RNAscope (<bold>P–b</bold>). Co-expression of RAB23 (green) and osteoblast marker RUNX2 (red) in the calvarial sutural section at E17.5 is shown by immunohistochemical staining (<bold>P–c</bold>), nuclear staining (blue). RAB23 protein expression in the sutures at E15.5 is shown by western blotting (<bold>P–d</bold>). fb: frontal bone, pb: parietal bone, ipb: interparietal bone, fs: frontal suture, ss: sagittal suture, ls: lambdoid suture. Scale bar: 500 µm (<bold>a</bold>), 100 µm (<bold>b, c</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55829-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>RAB23 protein expression in WT and <italic>Rab23<sup>-/-</sup></italic> mouse calvaria derived primary cells.</title><p>Protein extracted from Wt and RAB23 deficient <italic>Rab23<sup>-/-</sup></italic> mouse calvaria derived primary cells show RAB23 expression at 28 kDa in the Wt cells, while RAB23 is not expressed in the <italic>Rab23<sup>-/-</sup></italic> cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55829-fig1-figsupp1-v2.tif"/></fig></fig-group><p>At E18.5, 5% of <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures exhibited unilateral suture fusion (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Compared to Wt samples (<xref ref-type="fig" rid="fig1">Figure 1I</xref>), unfused <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures showed abnormal bony protrusions from parietal bones toward interparietal bone (<xref ref-type="fig" rid="fig1">Figure 1J</xref>) or ectopic bones in the lambdoid suture (<xref ref-type="fig" rid="fig1">Figure 1K</xref>). At this stage, <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures were narrower than Wt lambdoid sutures (<xref ref-type="fig" rid="fig1">Figure 1L</xref>). As 95% of <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures were consistently patent at E18.5 they were chosen as a model to study the role of RAB23 in osteogenesis. <italic>Rab23<sup>-/-</sup></italic> mice die neonatally, therefore, analysis of <italic>Rab23<sup>-/-</sup></italic> lambdoid suture beyond the E18.5 stage was assessed by in vitro calvarial explant culture (<xref ref-type="bibr" rid="bib52">Rice et al., 2003b</xref>; <xref ref-type="fig" rid="fig1">Figure 1M</xref>). Wt and patent <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures harvested for culture at E18.5, <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures fused predictably after 3 days of culture (<xref ref-type="fig" rid="fig1">Figure 1N,O</xref>).</p></sec><sec id="s2-2"><title><italic>Rab23</italic> expression in calvaria and sutures</title><p><italic>Rab23</italic> mRNA expression was analyzed in whole calvaria and tissue sections by in situ hybridization and protein expression by immunohistochemical staining and western blotting. <italic>Rab23</italic> was expressed in suture mesenchyme with the strongest signal in interfrontal, sagittal and coronal sutures and parietal bone side of the lambdoid suture (<xref ref-type="fig" rid="fig1">Figure 1P–a</xref>). Analysis of tissue sections revealed <italic>Rab23</italic> expression in the osteogenic fronts of the calvarial sutures and throughout the sutural mesenchyme (<xref ref-type="fig" rid="fig1">Figure 1P–b</xref>). RAB23 was expressed in the lambdoid sutural osteogenic fronts and in the underlying cartilage. Co-expression with RUNX2 confirmed the cells in the osteogenic front to be osteoprogenitor or osteoblast (<xref ref-type="fig" rid="fig1">Figure 1P–c</xref>). The <italic>Rab23</italic> expression pattern was consistent with the phenotype of synostosed calvarial sutures observed in the <italic>Rab23<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig1">Figure 1B,C and E</xref>). Western blotting of proteins extracted from E15.5 Wt calvarial frontal, sagittal and lambdoid sutures along with their osteogenic fronts confirmed the presence of RAB23 protein in the suture (<xref ref-type="fig" rid="fig1">Figure 1P–d</xref>).</p></sec><sec id="s2-3"><title><italic>Rab23<sup>-/-</sup></italic> mice exhibit elevated levels of <italic>Fgf10</italic> and <italic>Pitx2</italic> in the calvaria and suture</title><p>To investigate differentially expressed genes between Wt and <italic>Rab23<sup>-/-</sup></italic> calvaria and to find candidate genes responsible for the craniosynostosis in the RAB23-deficient mice, we performed a microarray-based gene expression analysis of whole Wt and <italic>Rab23<sup>-/-</sup></italic> calvaria samples excluding the skin and underlying brain at E15.5 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Our analysis revealed 223 significantly differentially expressed genes between the Wt and <italic>Rab23<sup>-/-</sup></italic> calvaria (t-test, p&lt;0.05) (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, MIAME-compliant data has been deposited in GEO database as source data, GEO accession GSE140884). Among these genes, 115 genes were upregulated (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, red) and 108 genes were downregulated (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, green). <italic>Fgf10</italic> was found to be overexpressed in the microarray in <italic>Rab23<sup>-/-</sup></italic> calvaria (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). <italic>Fgf10</italic> was selected as a candidate for further analysis as it has previously been shown to be expressed early in calvarial development and has been implicated in craniosynostosis pathogenesis (<xref ref-type="bibr" rid="bib18">Hajihosseini et al., 2009</xref>; <xref ref-type="bibr" rid="bib65">Veistinen et al., 2009</xref>). <italic>Fgf10</italic> expression was elevated in whole calvarial mesenchyme, lambdoid sutural mesenchymal tissue and in calvaria derived (CD) mesenchymal cells at E15.5 as assessed by RT-qPCR (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Our microarray analysis also showed that the transcription factor <italic>Pitx2</italic> was elevated in <italic>Rab23<sup>-/-</sup></italic> calvaria (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). <italic>Pitx2</italic> is a well-documented upstream regulator of <italic>Fgf10</italic> and may act in a reciprocal regulatory loop with FGF10 during early organogenesis (<xref ref-type="bibr" rid="bib1">Al Alam et al., 2012</xref>). We found that <italic>Pitx2</italic> was overexpressed both in the <italic>Rab23<sup>-/-</sup></italic> calvaria and in <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). <italic>Pitx2</italic> overexpression was further observed in <italic>Rab23<sup>-/-</sup></italic> calvaria by whole-mount in situ hybridization in and surrounding the interparietal bone (<xref ref-type="fig" rid="fig2">Figure 2F</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Gene expression analysis in Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture.</title><p>(<bold>A</bold>) Wt and <italic>Rab23<sup>-/-</sup></italic> calvaria at E15.5 (dotted ring, excluding skin) processed for Illumina based microarray (n = 3 for each age and genotype). (<bold>B</bold>) Analysis of mRNA based microarray data by Chipster, a bioinformatics tool, reveals that 223 genes are differentially expressed (<italic>t</italic>-test, p&lt;0.05, 115 genes are upregulated, red and 108 genes are downregulated, green) in <italic>Rab23<sup>-/-</sup></italic> calvaria, represented by volcano plot (n = 3 for each age and genotype). Fold change of genes is calculated by arithmetic mean in linear scale and shown in the volcano plot. Fold change &gt;1 (up-regulated gene), fold change &lt; 1 (down-regulated gene). The gene list is provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. (<bold>C</bold>) Represents individual searches of genes based on their contribution of suture fusion reveals <italic>Fgf10</italic> as a candidate gene and <italic>Pitx2</italic> as another developmentally important gene that can regulate <italic>Fgf10</italic> expression. Both genes are upregulated in <italic>Rab23<sup>-/-</sup></italic> calvaria. (<bold>D, E</bold>) RT-qPCR analysis of <italic>Fgf10</italic> (<bold>D</bold>) and <italic>Pitx2</italic> (<bold>E</bold>) mRNA extracted from E15.5 Wt and <italic>Rab23<sup>-/-</sup></italic> calvaria (excluding skin), cultured calvaria derived primary cells (CDC) and from lambdoid sutural tissue reveals that <italic>Fgf10</italic> and <italic>Pitx2</italic> are overexpressed in <italic>Rab23<sup>-/-</sup></italic> samples (n = 3 calvaria and eight lambdoid sutures for each genotype). Gene expressions were normalized by <italic>18S rRNA</italic>. Data are represented as mean ± SD, paired Student’s <italic>t</italic>-test was used and as relative gene expression is shown using ΔΔCт values. Statistical significance was defined as a p<italic>-value</italic> &lt;0.05 (*), p<italic>-value</italic> &lt;0.005 (**). (<bold>F</bold>) <italic>Pitx2</italic> expression analysis by whole-mount ISH in Wt and <italic>Rab23<sup>-/-</sup></italic> calvaria at E15.5. Arrows indicate <italic>Pitx2</italic> overexpression in the lambdoid suture. pb: parietal bone, ipb: interparietal bone, ls: lambdoid suture. Scale bar: 500 µm. (<bold>G</bold>) RT-qPCR expression analysis of <italic>Fgfr1b, Fgfr2b</italic> and <italic>Fgfr2c</italic> mRNA from E15.5 Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture reveals <italic>Fgfr1b</italic> overexpression in <italic>Rab23<sup>-/-</sup></italic> sample (n = 8 for each genotype). Gene expressions were normalized by <italic>18S rRNA</italic>. Data are represented as mean ± SD, paired Student’s <italic>t</italic>-test was used and relative gene expression is shown using ΔΔCт values. Statistical significance was defined as a <italic>P-value </italic>&lt;0.05 (*). (<bold>H, I</bold>) Western blotting of proteins extracted from Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture at E15.5 (<bold>H</bold>) and relative intensity measurement (<bold>I</bold>) reveals over expression of FGFR1 in the <italic>Rab23<sup>-/-</sup></italic> lambdoid suture (n = 6 for each genotype). Data represented as mean ± SD, paired Student’s <italic>t</italic>-test was used. Statistical significance was defined as a p<italic>-value </italic>&lt;0.05 (*). (<bold>J</bold>) Exogenous FGF10 treatment for 3 hr on Wt calvaria derived (CD) cells and subsequent <italic>Fgfr1b and Fgfr2b</italic> mRNA analysis by q-PCR shows induction of <italic>Fgfr1b</italic> expression in FGF10 treated cells compare to untreated Wt CD cells (n = 3 for each genotype). Gene expressions were normalized by <italic>18S rRNA</italic>. Data are represented as mean ± SD, paired Student’s <italic>t</italic>-test was used and relative gene expression is shown using ΔΔCт values. Statistical significance was defined as a <italic>P-value</italic>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55829-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>FGFR1 expression in Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture.</title><p>Immunohistochemical staining of FGFR1 in the sectioned Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture at E17.5 and E18.5. Enzmet-mediated detection shows FGFR1 expression (blue arrow) in the lambdoid suture. Counter stained with nuclear fast red. pb: parietal bone, ipb: interparietal bone. Dotted lines indicate bone edge. Scale bar: 50 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55829-fig2-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>FGF10-induced upregulation of <italic>Fgfr1b</italic> expression in <italic>Rab23<sup>-/-</sup></italic> lambdoid suture</title><p>We assessed the expression of FGF10-specific receptors <italic>Fgfr1b, Fgfr2b,</italic> also <italic>Fgfr2c</italic> in Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid sutural mesenchymal tissue. Our analysis showed elevated <italic>Fgfr1b</italic> expression and a non-significant upregulation of <italic>Fgfr2b</italic> in <italic>Rab23<sup>-/-</sup></italic> samples (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). FGFR1 protein levels were found to be elevated in <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures compared to Wt samples when analyzed by western blotting (<xref ref-type="fig" rid="fig2">Figure 2H,I</xref>) and by immunohistochemical staining (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). The expression of <italic>Fgfr2c</italic> was unchanged (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). To test whether the upregulation of <italic>Fgfr1b</italic> and <italic>Fgfr2b</italic> expression was due to the high levels of FGF10 ligand present in the <italic>Rab23<sup>-/-</sup></italic> lambdoid suture, we isolated E15.5 wild-type calvaria derived (CD) mesenchymal cells and treated them with exogenous FGF10 (250 ng/ml) for 3 hr. <italic>Fgfr1b</italic> and <italic>Fgfr2b</italic> expression levels were then assessed by RT-qPCR. We found a significant (p=0.05) upregulation of <italic>Fgfr1b</italic> expression and a slight upregulation of <italic>Fgfr2b</italic> expression in the cultured CD mesenchymal cells after exogenous FGF10 stimulation, indicating FGFR1b as a target of FGF10 in the calvarial mesenchyme (<xref ref-type="fig" rid="fig2">Figure 2J</xref>).</p></sec><sec id="s2-5"><title>Opposing MAPK-RUNX2 and Hh-GLI1 signaling in <italic>Rab23<sup>-/-</sup></italic> lambdoid suture</title><p>FGF signaling has been shown to activate MAPK signaling pathway subtypes pERK and p38 in suture morphogenesis and osteoblast differentiation (<xref ref-type="bibr" rid="bib30">Kyono et al., 2012</xref>; <xref ref-type="bibr" rid="bib48">Pfaff et al., 2016</xref>; <xref ref-type="fig" rid="fig3">Figure 3A</xref>). In <italic>Rab23<sup>-/-</sup></italic> lambdoid suture, we found decreased p38 and elevated pERK1/2 and RUNX2 expressions compare to Wt samples (<xref ref-type="fig" rid="fig3">Figure 3B–G</xref>). To test whether the upregulation of RUNX2 expression was due to the high levels of FGF10 present in the <italic>Rab23<sup>-/-</sup></italic> lambdoid suture, we isolated E15.5 <italic>Rab23<sup>-/-</sup></italic> calvaria derived (CD) mesenchymal cells and treated them with exogenous FGF10 (500 ng/ml) for 2 and 4 hr. <italic>Runx2</italic> expression levels were then assessed by RT-qPCR. We found a significant (p&lt;0.05) upregulation of <italic>Runx2</italic> expression at both time points compare to untreated samples, indicating that RUNX2 as a target of FGF10 in the calvarial mesenchyme (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Since ERK1/2 signaling regulates Hh and GLI expression, and RAB23 is a known negative regulator of Hh signaling (<xref ref-type="bibr" rid="bib8">Eggenschwiler et al., 2001</xref>), we further assayed <italic>Hh</italic>, <italic>Gli1, Gli2,</italic> and <italic>Gli3</italic> transcripts extracted from Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid sutural mesenchyme at E15.5. We detected a dramatic increase in the expression of <italic>Hh</italic> (<xref ref-type="fig" rid="fig3">Figure 3I</xref>) and <italic>Gli1</italic> (<xref ref-type="fig" rid="fig3">Figure 3J</xref>), a sutural stem cell marker (<xref ref-type="bibr" rid="bib75">Zhao et al., 2015</xref>). Although <italic>Gli3</italic> expression is not changed, a functional change in the ratio of GLI3FL to GLI3R may still possible (<xref ref-type="bibr" rid="bib67">Veistinen et al., 2017</xref>). As TGFβ-superfamily members have also been shown to regulate suture patency (<xref ref-type="bibr" rid="bib28">Kim et al., 1998</xref>; <xref ref-type="bibr" rid="bib29">Komatsu et al., 2013</xref>; <xref ref-type="bibr" rid="bib47">Pan et al., 2017</xref>), we assayed both pSMAD1/5/8 and pSMAD2/3 expressions but found no difference between Wt and mutant samples (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Analysis of MAPK signaling in Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture.</title><p>(<bold>A</bold>) Represents two downstream pathway subtypes p38 and ERK of MAPK signaling involve in RUNX2 activation and suture fusion. (<bold>B, C</bold>) Western blotting analysis of pERK44/42 and α-ERK44/42 protein levels extracted from Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture at E15.5 (<bold>B</bold>) and relative intensity measurement (<bold>C</bold>) shows higher pERK44 and pERK42 levels in <italic>Rab23<sup>-/-</sup></italic> lambdoid suture (n = 6 for each genotype). Data represented as mean ± SD, paired Student’s <italic>t</italic>-test was used. Statistical significance was defined as a <italic>P-value</italic> &lt;0.05 (*). (<bold>D, E</bold>) Western blotting analysis of phospho-p38 and p38 protein levels extracted from Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture at E15.5 (<bold>D</bold>) and relative intensity measurement (<bold>E</bold>) shows lower phospho-p38 and p38 levels in <italic>Rab23<sup>-/-</sup></italic> lambdoid suture (n = 6 for each genotype). Data represented as mean ± SD, paired Student’s <italic>t</italic>-test was used. Statistical significance was defined as a p<italic>-value</italic> &lt;0.05 (*), p<italic>-value</italic> &lt;0.005 (**). (<bold>F, G</bold>) Western blotting analysis of RUNX2 protein level extracted from Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture at E15.5 (<bold>F</bold>) and relative intensity measurement (<bold>G</bold>) shows higher RUNX2 level in <italic>Rab23<sup>-/-</sup></italic> lambdoid suture (n = 6 for each genotype). Data represented as mean ± SD, paired Student’s <italic>t</italic>-test was used. Statistical significance was defined as a p<italic>-value</italic> &lt;0.05 (*). (<bold>H</bold>) <italic>Runx2</italic> expression analysis by RT-qPCR in exogenous FGF10 treated (500 ng/ml) and untreated <italic>Rab23<sup>-/-</sup></italic> calvaria derived cells at 2 and 4 hr. (n = 3 for each genotype). Gene expressions were normalized by <italic>18S rRNA</italic>. Data are represented as mean ± SD, paired Student’s <italic>t</italic>-test was used and relative gene expression is shown using ΔΔCт values. Statistical significance was defined as a <italic>P-value</italic> &lt;0.05 (*), <italic>P-value</italic> &lt;0.005 (**). (<bold>I, J</bold>) RT-qPCR expression analysis of hedgehog signaling components <italic>Hh</italic> (<bold>H</bold>), <italic>Gli1</italic>, <italic>Gli2</italic> and <italic>Gli3</italic> (<bold>I</bold>) in the Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture reveals overexpression of <italic>Hh</italic> and <italic>Gli1</italic> in <italic>Rab23<sup>-/-</sup></italic> lambdoid suture (n = 8 for each genotype). Gene expressions were normalized by <italic>18S rRNA</italic>. Data are represented as mean ± SD, paired Student’s <italic>t</italic>-test was used and relative gene expression is shown using ΔΔCт values. Statistical significance was defined as a <italic>P-value</italic> &lt;0.05 (*), <italic>P-value</italic> &lt;0.005 (**). n.s: non-significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55829-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>pSMAD1/5/8 and pSMAD2/3 expression in Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture.</title><p>(<bold>A–D</bold>) Represents pSMAD1/5/8 (<bold>A, B</bold>) and pSMAD2/3 (<bold>C, D</bold>) in the Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures at E15.5 shows a similar level of expressions in both samples analyzed by western blotting (n = 3). Data represented as mean ± SD, paired Student’s <italic>t</italic>-test was used. n.s represents non-significant.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55829-fig3-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title><italic>Rab23<sup>-/-</sup></italic> lambdoid suture and MEF cells show increased osteoprogenitor cell proliferation</title><p>As FGF10-pERK1/2 signaling and RUNX2 are known to regulate suture osteoprogenitor proliferation (<xref ref-type="bibr" rid="bib28">Kim et al., 1998</xref>; <xref ref-type="bibr" rid="bib50">Qin et al., 2019</xref>), we assessed co-expression of EdU and RUNX2 in the WT and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture. EdU and RUNX2 co-localized in the osteogenic fronts indicating that the proliferating cells are osteoprogenitors (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>). We analyzed the proliferation in Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures (<xref ref-type="fig" rid="fig4">Figure 4C–H</xref>). EdU pulsed <italic>Rab23<sup>-/-</sup></italic> samples showed more proliferating cells in the osteogenic fronts compared to Wt (<xref ref-type="fig" rid="fig4">Figure 4C–H</xref>). In addition, increased level of cell proliferation was observed in <italic>Rab23<sup>-/-</sup></italic> derived mouse embryonic fibroblast (MEF) cells (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). <italic>Rab23<sup>-/-</sup></italic> calvaria derived cells also had an elevated number of total cells at different passages (P<sup>1</sup> to P<sup>3</sup>) when compared to Wt calvaria derived cells (<xref ref-type="fig" rid="fig4">Figure 4J</xref>). Increased proliferation in the sutures can result in a larger pool of osteoprogenitor cells and enhanced osteogenesis (<xref ref-type="bibr" rid="bib31">Lana-Elola et al., 2007</xref>; <xref ref-type="bibr" rid="bib52">Rice et al., 2003b</xref>). Taken together, this data shows that RAB23 is needed to repress proliferation in undifferentiated mesenchymal cells.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Cell proliferation analysis in Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid sutural cells and MEF cells.</title><p>(<bold>A–H</bold>) EdU pulsed assay in the Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures at E17.5 shows proliferating cells in red color (<bold>A–F</bold>). Proliferating cells show co-localization with osteoprogenitor and osteoblast marker RUNX2 (green) in the osteogenic front (inset, white arrow) in both Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture (<bold>A, B</bold>). Analysis of EdU pulsed cells (<bold>C–F</bold>) together with nuclear staining (<bold>E, F</bold>) in the Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture and subsequent quantification revealed that <italic>Rab23<sup>-/-</sup></italic> sutures show higher cell proliferation as percentage of EdU-positive cells compare to total cells (<bold>G</bold>) and percentage of EdU-positive cells only (<bold>H</bold>) in those sutures are higher compare to Wt samples (n = 4 for each genotype). Data represented as mean ± SD, paired Student’s <italic>t</italic>-test was used. Statistical significance was defined as a <italic>P</italic>-value &lt;0.005 (**). pb: parietal bone, ipb: interparietal bone, ls: lambdoid suture, of: osteogenic front. Scale bar: 100 µm. (<bold>I</bold>) EdU incorporation in the cultured Wt and <italic>Rab23<sup>-/-</sup></italic> MEF cells isolated from E13.5 embryos show 8–15% more cell proliferation (DNA duplication) in <italic>Rab23<sup>-/-</sup></italic> samples compare to corresponding Wt samples (n = 3 for each genotype). Data represented as mean ± SD, paired Student’s <italic>t</italic>-test was used. Statistical significance was defined as a p<italic>-value</italic> &lt;0.05 (*). (<bold>J</bold>) Represents passaging (P<sup>1</sup> to P<sup>3</sup> ) of Wt and <italic>Rab23<sup>-/-</sup></italic> calvaria derived primary cells in the culture show the total number of <italic>Rab23<sup>-/-</sup></italic> cells (ml<sup>−1</sup>) in each passage increases more rapidly than Wt cells, while the cell viability (determined by trypan blue) and cell size were similar in all cell lines. (n = 3 for each genotype). Data represented as mean ± SD, paired Student’s <italic>t</italic>-test was used. Statistical significance was defined as a p-value &lt;0.005 (**), p<italic>-value</italic> &lt;0.001 (***).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55829-fig4-v2.tif"/></fig></sec><sec id="s2-7"><title>RAB23 regulates suture patency through a MEK-driven mechanism</title><p>Our data suggest that <italic>Rab23<sup>-/-</sup></italic> lambdoid suture undergoes fusion through aberrant FGF signaling, specifically by activating pERK1/2 signaling, RUNX2 and enhanced cell proliferation of osteoprogenitor cells. To test this, we aimed to normalize the <italic>Rab23<sup>-/-</sup></italic> lambdoid suture by inhibiting the activation of MEK1/2, a downstream component of the MAPK-ERK1/2 signaling pathway by using MEK1/2 inhibitor U0126. We cultured E18.5 Wt and <italic>Rab23<sup>-/-</sup></italic> whole calvaria in osteogenic growth medium up to 72 hr. To confirm that lambdoid sutures were patent at time point zero, the vital bone dye calcein green was used to detect the bone edges. Calcein green was administered to pregnant females 24 hr before samples were taken. Half of the <italic>Rab23<sup>-/-</sup></italic> calvaria were treated with U0126 and half of the <italic>Rab23<sup>-/-</sup></italic> calvaria samples were untreated (<xref ref-type="fig" rid="fig5">Figure 5A,B</xref>). None of the untreated <italic>Rab23<sup>-/-</sup></italic> (n = 0/12) and 84.34% of U0126 treated <italic>Rab23<sup>-/-</sup></italic> (n = 11/12) lambdoid sutures were rescued (<xref ref-type="fig" rid="fig5">Figure 5A,B</xref>). To confirm whether bones were fused or not, Wt, U0126 treated and untreated <italic>Rab23<sup>-/-</sup></italic> samples were further analyzed in tissue sections and by µ-CT (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> and <xref ref-type="video" rid="fig5video1">Figure 5—Videos 1</xref>–<xref ref-type="video" rid="fig5video3">3</xref>). None of the Wt lambdoid sutures were fused (n = 0/12). The same experiment (n = 4 in each genotype) was carried out with E17.5 samples and cultured for 4 days. Untreated <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures underwent suture fusion by day 4, while U0126-treated <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures remained patent during the culture period (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). The effect of U0126 on sutural cells was also analyzed by cell death assay and no effect was observed in U0126-treated lambdoid sutural cells (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>). U0126 treatment not only prevented suture fusion but it also normalized the level of osteoprogenitor cell proliferation (<xref ref-type="fig" rid="fig5">Figure 5D–G</xref>). EdU incorporation revealed that U0126 treated <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures (n = 8) exhibited reduced proliferation when compared to <italic>Rab23<sup>-/-</sup></italic> controls (n = 8) (<xref ref-type="fig" rid="fig5">Figure 5D–G</xref>) and normalized it to Wt levels (n = 8) after 24 hr of culture (<xref ref-type="fig" rid="fig5">Figure 5D,E</xref>). The proliferation in all genotypes decreased over time (<xref ref-type="fig" rid="fig5">Figure 5D–G</xref>). This indicates that RAB23 regulates suture patency through a MAPK-MEK-ERK-driven mechanism. pERK1/2 regulates RUNX2 and GLI1 expression in calvaria derived mesenchymal cells.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Rescuing <italic>Rab23<sup>-/-</sup></italic> lambdoid suture fusion with pERK1/2 inhibitor.</title><p>(<bold>A–C</bold>) In vivo calcein green incorporation followed by in vitro calvaria culture in osteogenic medium and adding alizarin red in medium allowed to follow the bone growth in the sutural site. Layout of lambdoid suture rescue study (<bold>A</bold>). E18.5 Wt and a double number of <italic>Rab23<sup>-/-</sup></italic> calvaria were cultured in vitro for 3 day. Half of the <italic>Rab23<sup>-/-</sup></italic> calvaria were taken for control (DMSO) treatment and the other half were treated with ERK1/2 inhibitor U0126. 100% of <italic>Rab23<sup>-/-</sup></italic> control sutures are fused by day 3 of culture (A, B, alizarin red bone staining and C, µ-CT images) while 83.34% of <italic>Rab23<sup>-/-</sup></italic> suture with U0126 treated shows no fusion (<bold>A, B</bold>). # indicates dropout of two samples from each group due to technical hindrance. Dotted lines indicate bone edge. pb: parietal bone, ipb: interparietal bone. Scale bar: 500 µm (<bold>B, C</bold>). (<bold>D–G</bold>) Represents EdU incorporation in the E18.5 calvaria after 24 hr and 48 hr of culture. EdU was added in the culture medium for additional 2 hr and cell proliferation analyzed in the sectioned Wt, control <italic>Rab23<sup>-/-</sup></italic> and U0126 treated <italic>Rab23<sup>-/-</sup></italic> lambdoid sutural samples (<bold>D, F</bold>). U0126 reduced the cell proliferation in <italic>Rab23<sup>-/-</sup></italic> samples compare to untreated <italic>Rab23<sup>-/-</sup></italic> samples at 24 hr and 48 hr. U0126 treated <italic>Rab23<sup>-/-</sup></italic> suture shows dramatic reduction of cell proliferation compare to untreated <italic>Rab23<sup>-/-</sup></italic> suture (<bold>D, E</bold>). The reduction of cell proliferation has shown consistent at 48 hr (<bold>F, G</bold>) (n = 8 for each genotype). Data represented as mean ± SD, paired Student’s <italic>t</italic>-test was used. Statistical significance was defined as a p-value &lt;0.05 (*), p-value &lt;0.005 (**), p-value &lt;0.001 (***). Scale bar: 200 µm (<bold>D, F</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55829-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Rescuing suture fusion in <italic>Rab23<sup>-/-</sup></italic> calvaria.</title><p>Tissue sections and hematoxilin staining of Wt, <italic>Rab23<sup>-/-</sup></italic> and U0126-treated <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures after 48 hr in vitro culture of E18.5 calvaria. Alizarin red added to the medium shows the bone growth. Control <italic>Rab23<sup>-/-</sup></italic> lambdoid suture shows suture fusion (inset), while U0126-treated <italic>Rab23<sup>-/-</sup></italic> suture rescues from suture fusion (n = 3 for each genotype). pb: parietal bone, ipb: interparietal bone. Scale bar: 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55829-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Rescuing suture fusion in E17.5 <italic>Rab23<sup>-/-</sup></italic> mice.</title><p>In vitro culture of Wt and <italic>Rab23<sup>-/-</sup></italic> calvaria at E17.5. Calvaria labeled with osteocalcin vital dye (administred to pregnant mothers 24 hr before sacrifice) to determine the suture patency. Subsequent culture continued in osteogenic medium containing alizarin red. Control <italic>Rab23<sup>-/-</sup></italic> calvaria undergo suture fusion at day 4, while <italic>Rab23<sup>-/-</sup></italic> suture that has treated with MEK inhibitor U0126 is rescued from suture fusion (n = 4 for each genotype). pb: parietal bone, ipb: interparietal bone. Scale bar: 500 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55829-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Effect of U0126 on Wt and <italic>Rab23<sup>-/-</sup></italic> lambdoid suture.</title><p>(<bold>A, B</bold>) Represents in situ apoptosis detection in the sectioned lambdoid suture of Wt, <italic>Rab23<sup>-/-</sup></italic> and U0126 treated <italic>Rab23<sup>-/-</sup></italic> calvaria after 24 hr as day-1 (<bold>A</bold>) and after 48 hr as day-2 (<bold>B</bold>) in vitro culture. Counterstaining was performed with methyl green (n = 3 for each genotype). Scale bar: 200 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55829-fig5-figsupp3-v2.tif"/></fig><media id="fig5video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-55829-fig5-video1.mp4"><label>Figure 5—video 1.</label><caption><title>Wt lambdoid suture after 72 hr in vitro culture.</title></caption></media><media id="fig5video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-55829-fig5-video2.mp4"><label>Figure 5—video 2.</label><caption><title><italic>Rab23<sup>-/-</sup></italic> lambdoid suture fused after 72 hr in vitro culture.</title></caption></media><media id="fig5video3" mime-subtype="mp4" mimetype="video" xlink:href="elife-55829-fig5-video3.mp4"><label>Figure 5—video 3.</label><caption><title>U0126 treated <italic>Rab23<sup>-/-</sup></italic> lambdoid suture remained open after 72 hr in vitro culture.</title><p>Google drive link of the videos: <ext-link ext-link-type="uri" xlink:href="https://drive.google.com/drive/folders/1HdfBudPgo2KMf94AlPxq568RCWzYp72z?usp=sharing">https://drive.google.com/drive/folders/1HdfBudPgo2KMf94AlPxq568RCWzYp72z?usp=sharing</ext-link>.</p></caption></media></fig-group><p>We analyzed the effect of the MEK1/2 inhibitor U0126, cyclopamine and the combined action of cyclopamine and U0126 on pERK1/2, RUNX2 and GLI1 expression levels in <italic>Rab23<sup>-/-</sup></italic> CD cells at 6, 24 and 48 hr of culture (<xref ref-type="fig" rid="fig6">Figure 6</xref>). After 6 hr of culture, the relative pERK1/2 levels were significantly reduced in U0126-treated <italic>Rab23<sup>-/-</sup></italic> cells compare to untreated <italic>Rab23<sup>-/-</sup></italic> cells. The downregulation of pERK1/2 continued in U0126-treated <italic>Rab23<sup>-/-</sup></italic> cells at 24 and 48 hr of culture compare to the untreated <italic>Rab23<sup>-/-</sup></italic> cells (<xref ref-type="fig" rid="fig6">Figure 6A,B</xref>). Whereas, RUNX2 expression significantly reduced only after 48 hr of U0126-treated <italic>Rab23<sup>-/-</sup></italic> cells (<xref ref-type="fig" rid="fig6">Figure 6A,C</xref>). U0126-treated <italic>Rab23<sup>-/-</sup></italic> cells showed gradual reduction of GLI1 expressions at 6 and 24 hr; however, it showed drastic reduction at 48 hr compared to untreated <italic>Rab23<sup>-/-</sup></italic> cells (<xref ref-type="fig" rid="fig6">Figure 6A,D</xref>). Further immunohistochemical expression of GLI1 was also found reduced in the U0126 treated <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures at 24 and 48 hr compared to untreated <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). The effect of cyclopamine and combined action of cyclopamine and U0126 on these cells showed that cyclopamine has no effect on pERK1/2 expression and can reduce RUNX2 expression only after prolonged exposure (48 hr) (<xref ref-type="fig" rid="fig6">Figure 6E-H</xref>). However, the combined action of cyclopamine and U0126 caused a rapid downregulation of RUNX2 (24 hr) (<xref ref-type="fig" rid="fig6">Figure 6E-H</xref>). These findings collectively indicate that pERK1/2 regulates RUNX2 and GLI1 expressions. Whereas, RUNX2 is a predominant downstream target of pERK1/2 and a weak target of GLI1.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>RUNX2 and GLI1 are downstream target of pERK1/2.</title><p>(<bold>A–D</bold>) Time-dependent effect of U0126 in regulating pERK1/2, RUNX2 and GLI1 expressions has been analyzed by western blotting in the proteins extracted from E15.5 <italic>Rab23<sup>-/-</sup></italic> CD cells. These cells were treated with or without U0126. Relative pERK1/2 levels in <italic>Rab23<sup>-/-</sup></italic> CD cells are drastically reduces upon U0126 exposure at 6 hr and also shows downregulation of pERK1/2 at 24 and 48 hr upon U0126 exposure compare to corresponding untreated <italic>Rab23<sup>-/-</sup></italic> CD cells (<bold>A, B</bold>). RUNX2 expression significantly reduces in <italic>Rab23<sup>-/-</sup></italic> CD cells only after 48 hr of U0126 exposures (<bold>A, C</bold>). GLI1 expression in <italic>Rab23<sup>-/-</sup></italic> CD cells sequentially downregulated upon U0126 exposures at 6, 24 and 48 hr (<bold>A, D</bold>) (n = 3 blots for each time points). (<bold>E–H</bold>) Time-dependent effect of cyclopamine (10 µM) and combined effect of cyclopamine (10 µM) and U0126 (5 µM) in regulating GLI1, pERK1/2, and RUNX2 expressions has been analyzed by western blotting in the proteins extracted from E15.5 <italic>Rab23<sup>-/-</sup></italic> CD cells. These cells were treated with or without cyclopamine and combined cyclopamine and U0126 for 6, 24 and 48 hr. Relative GLI1 levels are significantly reduces at every time points upon cyclopamine treatment and show further gradual reduction of GLI1 upon combined treatment of cyclopamine with U0126 (<bold>E–H</bold>). Relative pERK1/2 levels in <italic>Rab23<sup>-/-</sup></italic> CD cells are drastically reduces upon combined cyclopamine and U0126 exposure at 6 hr (<bold>E, F</bold>) and also shows downregulation of pERK1/2 at 24 and 48 hr upon combined cyclopamine and U0126 exposure compare to corresponding untreated <italic>Rab23<sup>-/-</sup></italic> CD cells (<bold>E, G, H</bold>). However, pERK1/2 level remain unchanged at every time points upon cyclopamine treatment alone. RUNX2 expression significantly reduces in <italic>Rab23<sup>-/-</sup></italic> CD cells after 24 hr by combined treatment of cyclopamine and U0126 (<bold>E, G, H</bold>), and only significantly reduces after 48 hr upon cyclopmine treatment alone. (n = 3 blots for each time points). Data represented as mean ± SD, paired Student’s <italic>t</italic>-test was used. Statistical significance was defined as a p-value &lt;0.05 (*), p-value &lt;0.005 (**), p-value &lt;0.001 (***).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55829-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>GLI1 is a downstream target of pERK1/2 Immunohistochemical staining shows GLI1 expression in <italic>Rab23<sup>-/-</sup></italic> and U0126-treated <italic>Rab23<sup>-/-</sup></italic> lambdoid sutural sections at 24 and 48 hr of in vitro culture of E18.5 samples.</title><p>Blue arrows indicate GLI1 expression. Counter stained with nuclear fast red. pb: parietal bone, ipb: interparietal bone. Dotted lines indicate bone edge. Scale bar: 50 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55829-fig6-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The calvarial suture allows us to study many developmental processes that regulate osteogenesis and skull morphogenesis. Normal development is ensured by the correct temporal and spatial coordination of skeletal patterning, mesenchymal stem cell niche regulation, condensation formation, osteoprogenitor expansion, and osteoblast differentiation and function. In this study, we generated <italic>Rab23-</italic>deficient mice that survive into late gestation and they exhibit multiple suture craniosynostosis. We show that RAB23 regulates the sutural stem cell niche marker GLI1, represses Hh, and inhibits osteoprogenitor expansion. RAB23 also represses FGF10-driven pERK1/2 signaling which has the multiple effect of directly regulating osteoprogenitor development, RUNX2-mediated differentiation and of repressing GLI1. Therefore, RAB23 coordinates suture biogenesis by regulating FGF-ERK1/2-RUNX2 activity, as well as the activation of GLI1. In an attempt to study complex developmental events, we have utilized both primary cells and organ culture approaches. However, one can also take a more cell biological approach using immortalized cells remote from the external factors and by using this standardized approach it may be easier to understand the effects of a specific intervention. This will be help deciphering the role of RAB23, specifically during endocytosis.</p><p>FGF10 signaling regulates early osteogenesis: it is expressed in the osteogenic condensation, and is implicated in the pathogenesis of several craniosynostotic models (<xref ref-type="bibr" rid="bib63">Twigg and Wilkie, 2015</xref>; <xref ref-type="bibr" rid="bib65">Veistinen et al., 2009</xref>). Here, we show that <italic>Fgf10,</italic> its receptor FGFR1b and the FGF activator <italic>Pitx2</italic>, are all upregulated in <italic>Rab23-</italic>deficient calvaria. It is surprising that the FGFR1b splice form, which is normally expressed in epithelia, is upregulated in the mesenchymal suture. However, this is not without precedent. While FGFRc isoforms are predominantly expresses in the mesenchyme and b isoforms in the epithelium, their expression is not mutually exclusive and FGFR1b is known to be expressed by late embryonic murine lung mesenchymal cells and also in the zebrafish in the sutural mesenchyme (<xref ref-type="bibr" rid="bib2">Al Alam et al., 2015</xref>; <xref ref-type="bibr" rid="bib52">Rice et al., 2003b</xref>; <xref ref-type="bibr" rid="bib53">Rice et al., 2004</xref>; <xref ref-type="bibr" rid="bib60">Topczewska et al., 2016</xref>). Under pathological/force conditions, mis-expression of splice forms can occur. Occasionally, Apert craniosynostosis syndrome is caused by heterozygous Alu-insertions or large deletions in the FGFR2c domain. These rare mutations induce abnormal expression of the FGFR2b splice form alongside FGFR2c splice form in mesenchymal cells. This permits cells to respond to both b- and c-activating FGF ligands including FGF10 (<xref ref-type="bibr" rid="bib3">Bochukova et al., 2009</xref>; <xref ref-type="bibr" rid="bib44">Oldridge et al., 1999</xref>). Analyzing the MAPK pathway in <italic>Rab23<sup>-/-</sup></italic> lambdoid sutures we show that p38 signaling is decreased and pERK1/2 increased. FGFR activation of pERK1/2 is important for several stages of osteoblastogenesis, including osteoprogenitor proliferation, and in the induction and stabilization of RUNX2 (<xref ref-type="bibr" rid="bib6">Choi et al., 2008</xref>; <xref ref-type="bibr" rid="bib72">Yoon et al., 2014</xref>). Augmentation of pERK1/2 signaling either through overactivation of <italic>FGFRs</italic>, downregulation of its inhibitors, or downregulation of <italic>ERF</italic> that regulates the export of pERK from the nucleus, all result in craniosynostosis (<xref ref-type="bibr" rid="bib35">Lee et al., 2018a</xref>; <xref ref-type="bibr" rid="bib36">Lee et al., 2018b</xref>; <xref ref-type="bibr" rid="bib59">Timberlake et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Twigg et al., 2013</xref>).</p><p>Although RUNX2 is a substrate for both p38 and pERK1/2, pERK1/2 can activate RUNX2 on average six times more efficiently than p38 (<xref ref-type="bibr" rid="bib14">Ge et al., 2012</xref>). In addition, ERK1/2 binding to RUNX2 through MAPK D site has greater affinity than p38 binding and more sensitive to osteoblast differentiation during calvaria explant or primary osteoblast culture (<xref ref-type="bibr" rid="bib12">Franceschi and Ge, 2017</xref>; <xref ref-type="bibr" rid="bib14">Ge et al., 2012</xref>). The importance of pERK1/2 regulation of RUNX2 during osteogenesis is shown in this study by the reversal of the craniosynostotic phenotype in <italic>Rab23<sup>-/-</sup></italic> mice. p38 has been implicated in the skull phenotypes of craniosynostotic mice where it may regulate the development and growth of cartilage elements (<xref ref-type="bibr" rid="bib69">Wang et al., 2010</xref>; <xref ref-type="bibr" rid="bib70">Wang et al., 2012</xref>). Opposing roles of MAPK pathway subtypes p38 and pERK1/2 in cartilage development are well documented (<xref ref-type="bibr" rid="bib39">Ma et al., 2019</xref>; <xref ref-type="bibr" rid="bib43">Oh et al., 2000</xref>; <xref ref-type="bibr" rid="bib58">Stanton et al., 2003</xref>).</p><p>Commonality of etiological mechanisms is suggested by the overlapping skeletal phenotypes exhibited in Carpenter syndrome and Grieg cephalopolysyndactyly syndrome patients as well as their mouse disease models, <italic>Gli3<sup>Xt−J/Xt−J</sup></italic> (<xref ref-type="bibr" rid="bib54">Rice et al., 2010</xref>) and <italic>Rab23<sup>-/-</sup></italic> (this study). Specifically, postaxial polydactyly in the forelimb, preaxial polydactyly in the hindlimb and lambdoid and interfrontal suture craniosynostosis (<xref ref-type="bibr" rid="bib8">Eggenschwiler et al., 2001</xref>; <xref ref-type="bibr" rid="bib23">Jenkins et al., 2007</xref>; <xref ref-type="bibr" rid="bib26">Kalff-Suske et al., 1999</xref>; <xref ref-type="bibr" rid="bib68">Vortkamp et al., 1991</xref>). Collectively suggest that craniosynostosis and polysyndactyly are overlapping phenotypes of aberrant FGF and Hh signaling. Aberrant osteogenesis and suture obliteration in the <italic>Gli3<sup>Xt−J/Xt−J</sup></italic> mouse is caused by concomitant derepression of GLI3 and augmentation of IHH which activates the osteogenic master regulatory transcription factor RUNX2 (<xref ref-type="bibr" rid="bib67">Veistinen et al., 2017</xref>). Analysis of early <italic>Rab23<sup>-/-</sup></italic> embryos suggests that RAB23 also has a role in promoting the production of GLI3 repressor (<xref ref-type="bibr" rid="bib9">Eggenschwiler et al., 2006</xref>). In both <italic>Gli3<sup>Xt−J/Xt−J</sup></italic> and <italic>Rab23<sup>-/-</sup></italic> calvaria elevated Hh signaling results in an upregulation of the transcription factor Gli1, and presumably the mesenchymal stem niche which it labels.</p><p>Previously, we have shown that FGF10 upregulates <italic>Hh</italic> and its receptor <italic>Patch1</italic> during facial development (<xref ref-type="bibr" rid="bib53">Rice et al., 2004</xref>). Here, we show FGF10 upregulates Runx2. Our study revealed that inhibition of pERK1/2 prevented <italic>Rab23<sup>-/-</sup></italic> lambdoid suture fusion by decreasing osteoprogenitor proliferation and GLI1 expression (<xref ref-type="fig" rid="fig5">Figures 5</xref> and <xref ref-type="fig" rid="fig6">6</xref>). We further showed that combined and individual inhibition of GLI1 and pERK1/2 in <italic>Rab23<sup>-/-</sup></italic> calvarial cells downregulated RUNX2 and GLI1 (<xref ref-type="fig" rid="fig6">Figure 6</xref>) and that this effect was exaggerated in <italic>Rab23<sup>-/-</sup></italic> cells. Phenotypic analyses of compound <italic>Rab23;Smoothened</italic> early embryonic mice shows that RAB23 can regulate GLI independently of Smoothened (<xref ref-type="bibr" rid="bib9">Eggenschwiler et al., 2006</xref>), and the regulation of GLI1 by pERK1/2 suggests a mechanism how this might occur (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Non-canonical regulation GLI1 through tyrosine kinase activity has been documented during carcinogenesis, with activation of GLI1 promoting stemness through an increase in transcriptional activity, nuclear localization or protein stability (<xref ref-type="bibr" rid="bib49">Pietrobono et al., 2019</xref>). However, the non-canonical repression of GLI1 has not been well described in a developmental context.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Model: regulation of suture patency by RAB23.</title><p>In the developing calvaria RAB23 regulates FGFR signaling by repressing FGF10 expression. This regulates the delicate balance of osteoprogenitor proliferation and differentiation. RAB23 also known as a negative regulator of Hh signaling. The regulation of GLI1 through ERK1/2 and Hh in the mesenchymal stem cell niche is maintained along with RUNX2 during osteoprogenitor proliferation and differentiation. Thus, through a combination of FGF and Hh signaling, RAB23 tightly synchronizes suture morphogenesis and patency.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55829-fig7-v2.tif"/></fig><p>We show that RAB23 represses both FGF and Hh/GLI signaling (<xref ref-type="fig" rid="fig7">Figure 7</xref>). RAB23 coordinates suture morphogenesis and controls suture patency through three mechanisms: FGF10-pERK1/2 signaling, the repression of Hh targets through a canonical pathway, and through the repression of GLI1 by pERK1/2. GLI1 contributes in the regulation of the mesenchymal stem cell niche. FGF10-pERK1/2 and also Hh-GLI1 signaling regulate osteoprogenitor cell proliferation.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Strain, strain background <break/>(<italic>M. musculus</italic>, C3Heb/FeJ)</td><td><italic>Rab23opb2</italic> mice C3Heb/FeJ</td><td><xref ref-type="bibr" rid="bib8">Eggenschwiler et al., 2001</xref>; <xref ref-type="bibr" rid="bib27">Kasarskis et al., 1998</xref></td><td/><td/></tr><tr><td valign="top">Strain, strain background <break/>(<italic>M. musculus</italic>, C57/Bl6)</td><td valign="top"><italic>Rab23opb2</italic> mice C57Bl/6</td><td valign="top">This paper</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Cell lines (<italic>Mus musculus</italic>)</td><td valign="top"/><td valign="top">This paper</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal RAB23</td><td valign="top">Proteintech</td><td valign="top">Cat#11101–1-AP</td><td valign="top">WB: 1:1000, IHC: 1:250</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit monoclonal FGFR1</td><td valign="top">Cell signaling technology</td><td valign="top">Cat#9740</td><td valign="top">WB: 1:1000, IHC: 1:250</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit monoclonal p44/42</td><td valign="top">Cell signaling technology</td><td valign="top">Cat#4965S</td><td valign="top">WB: 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit monoclonal phospho-p44/42</td><td valign="top">Cell signaling technology</td><td valign="top">Cat#9101</td><td valign="top">WB: 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit monoclonal phospho-p38</td><td valign="top">Cell signaling technology</td><td valign="top">Cat#4631S</td><td valign="top">WB: 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal p38</td><td valign="top">Cell signaling technology</td><td valign="top">Cat#9212</td><td valign="top">WB: 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit monoclonal RUNX2</td><td valign="top">Cell signaling technology</td><td valign="top">Cat#8486</td><td valign="top">WB: 1:1000, IHC: 1:250</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal GLI1</td><td valign="top">Cell signaling technology</td><td valign="top">Cat#2643</td><td valign="top">WB: 1:1000, IHC: 1:250</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit monoclonal pSMAD2/3</td><td valign="top">Cell signaling technology</td><td valign="top">Cat#8828</td><td valign="top">WB: 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal pSMAD1/5/8</td><td valign="top">Millipore</td><td valign="top">Cat#AB3848</td><td valign="top">WB: 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal RUNX2</td><td valign="top">Santa Cruz Biotechnology</td><td valign="top">Cat# sc-390351</td><td valign="top">WB: 1:1000, IHC: 1:250</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse αTubulin</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat#T6199</td><td valign="top">1:2000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-rabbit IgG (H+L), Alexa 488</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#A-11008</td><td valign="top">1:500</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-mouse IgG (H+L), Alexa 546</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#A-110003</td><td valign="top">1:500</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-mouse IgG (H+L), Alexa 488</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#A-11001</td><td valign="top">1:500</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-rabbit 680LT</td><td valign="top">LI-COR</td><td valign="top">Cat#925–68021</td><td valign="top">1:5000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-rabbit 800CW</td><td valign="top">LI-COR</td><td valign="top">Cat#925–32211</td><td valign="top">1:5000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-mouse IRDye 800CW</td><td valign="top">LI-COR</td><td valign="top">Cat#925–32210</td><td valign="top">1:5000</td></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Enzmet HRP detection kit</td><td valign="top">Nanoprobes</td><td valign="top">Cat#6001</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Hoechst 33342</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# H3570</td><td valign="top">1:2000</td></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Pierce IP lysis buffer</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#87787</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">RevertAid reverse transcriptase</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#EP0441</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Random hexamer primer</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#SO142</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Ribolock RNase inhibitor</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#EO0381</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Odyssey blocking buffer</td><td valign="top">LI-COR</td><td valign="top">927–40100</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">FGF10</td><td valign="top">R and D</td><td valign="top">Cat#6224-FG-025</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Complete protease inhibitor cocktail</td><td valign="top">Roche</td><td valign="top">Cat#04693116001</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Complete phosphatase inhibitor cocktail</td><td valign="top">Roche</td><td valign="top">Cat#04906845001</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Nucleospin RNA</td><td valign="top">Biotop</td><td valign="top">Cat#740955.250</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Click-iT EdU Alexa Fluor 594</td><td valign="top">Invitrogen</td><td valign="top">Cat#C10339</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">EdU (5-ethynyl-2´-deoxyuridine)</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat#A10044</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">U0126</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat#662005</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Alizarin-3-methyliminodiacetic acid</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat#A3882</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Calcein green</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat#C0875</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Apoptosis detection kit</td><td valign="top">Abcam</td><td valign="top">Cat#ab206386</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">Pierce BCA protein assay kit</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat#23225</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">KAPA SYBR FAST qPCR master mix (2X)</td><td valign="top">KAPA Biosystems</td><td valign="top">Cat#KK4601</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">4–20% Mini-PROTEAN TGX Gels</td><td valign="top">BIORAD</td><td valign="top">Cat#456–1094</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Pitx2</italic></td><td valign="top">This study</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;id=559098490">NM_001286942.1</ext-link></td><td valign="top"><italic>F: <named-content content-type="sequence">CCGCCTGGCAGTCACC</named-content></italic> <break/><italic>R: <named-content content-type="sequence">CTCCATTCCCGGTTATCGGC</named-content></italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Fgf10</italic></td><td valign="top">This study</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;id=226823275">NM_008002.4</ext-link></td><td valign="top">F: <named-content content-type="sequence">AGGCTGTTCTCCTTCACCAAG</named-content> <break/>R:<named-content content-type="sequence">ATGTTATCTCCAGGACACTGTACG</named-content></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Gli1</italic></td><td valign="top">This study</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;id=90186272">NM_010296.2</ext-link></td><td valign="top"><italic>F: <named-content content-type="sequence">CAGCATGGGAACAGAAGGACT</named-content></italic> <break/><italic>R: <named-content content-type="sequence">CTCTGGCTGCTCCATAACCC</named-content></italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Gli2</italic></td><td valign="top">This study</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;id=124487480">NM_001081125.1</ext-link></td><td valign="top"><italic>F: <named-content content-type="sequence">AACTTTTGTCTCCTCGGGTCC</named-content></italic> <break/><italic>R: <named-content content-type="sequence">CTGCTGTCCTCCAAGAGACC</named-content></italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Gli3</italic></td><td valign="top">This study</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;id=1447199263">NM_008130.3</ext-link></td><td valign="top"><italic>F: <named-content content-type="sequence">AAGCCCATGACATCTCAGCC</named-content></italic> <break/><italic>R: <named-content content-type="sequence">CTCGAGCCCACTGTTGGAAT</named-content></italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Hh</italic></td><td valign="top">This study</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;id=1720412662">XM_006535649.4</ext-link></td><td valign="top"><italic>F: <named-content content-type="sequence">AAGCAGGTTTCGACTGGGTC</named-content></italic> <break/><italic>R: <named-content content-type="sequence">CCACGGAGTTCTCTGCTTTCA</named-content></italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Fgfr1b</italic></td><td valign="top"><xref ref-type="bibr" rid="bib34">Lee et al., 2008</xref></td><td valign="top"/><td valign="top"><italic>F: <named-content content-type="sequence">GGGAATTAATAGCTCGGATGA</named-content></italic> <break/><italic>R: <named-content content-type="sequence">ACGCAGACTGGTTAGCTTCA</named-content></italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Fgfr2b</italic></td><td valign="top">This study</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;id=116089354">NM_201601.2</ext-link></td><td valign="top"><italic>F: <named-content content-type="sequence">TCAAGGTCCTGAAGCACTCG</named-content></italic> <break/><italic>R: <named-content content-type="sequence">CAGCATCCATCTCCGTCACA</named-content></italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Fgfr2c</italic></td><td valign="top">This study</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;id=116089348">NM_010207.2</ext-link></td><td valign="top"><italic>F: <named-content content-type="sequence">AACCAGAAGAGCCACCAACC</named-content></italic> <break/><italic>R: <named-content content-type="sequence">TAGTCCAACTGATCACGGCG</named-content></italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Runx2</italic></td><td valign="top">This study</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&amp;id=410110933">NM_001271631.1</ext-link></td><td valign="top"><italic>F: <named-content content-type="sequence">CAGTCCCAACTTCCTGTGCT</named-content></italic> <break/><italic>R: <named-content content-type="sequence">CCCATCTGGTACCTCTCCGA</named-content></italic></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>18S rRNA</italic></td><td valign="top"><xref ref-type="bibr" rid="bib42">Nishioka et al., 2010</xref></td><td valign="top"/><td valign="top"><italic>F: <named-content content-type="sequence">AAACGGCTACCACATCCAAG</named-content></italic> <break/><italic>R: <named-content content-type="sequence">CAATTACAGGGCCTCGAAAG</named-content></italic></td></tr><tr><td valign="top">Software</td><td valign="top">Fiji (Image J)</td><td valign="top">National Institute of Health</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://fiji.sc/">https://fiji.sc/</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software</td><td valign="top">Desktop micro-CT system</td><td valign="top">Bruker</td><td valign="top">SkyScan1272</td><td valign="top"/></tr><tr><td valign="top">Software</td><td valign="top">Nrecon, Desktop micro-CT system</td><td valign="top">Bruker</td><td valign="top">SkyScan1272</td><td valign="top"/></tr><tr><td valign="top">Software</td><td valign="top">Odyssey infrared imaging system</td><td valign="top">LI-COR Biosciences</td><td valign="top">Model 9120</td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Study approval</title><p>Animal experiments were approved by the University of Helsinki, Helsinki University Hospital and the Southern Finland Council Animal Welfare and Ethics committees. Permit ESAVI/11956/04.10.07/2017 (external) and KEK17-008 (internal).</p></sec><sec id="s4-2"><title>Mice</title><p><italic>Rab23<sup>opb2/opb2</sup></italic> (<italic>Rab23<sup>-/-</sup></italic>) mice were originally in C3Heb/Fej background were crossed into C57Bl/6J mouse strain (Charles River) for six or more generations with speed congenic method. The animals for breeding were selectively based on highest amount of C57 SNP markers (Illumina mouse chip array) to speed up strain change. After four generations more than 89% of SNPs were on C57. The genotype of all mouse and embryos were verified with PCR-based genotyping as previously described (<xref ref-type="bibr" rid="bib10">Eggenschwiler and Anderson, 2000</xref>; <xref ref-type="bibr" rid="bib27">Kasarskis et al., 1998</xref>).</p></sec><sec id="s4-3"><title>Microarray and RT-qPCR</title><p>Analysis of the RNA expression was performed using Illuminan Mouse WG-6v2 microchips. RNA was isolated from E15 calvaria from <italic>Rab23<sup>-/-</sup></italic> embryos and Wt littermates using Machrey-Nagel Nucleospin RNA II isolation kit. Labeling and chip run were performed by the Technology Centre, Institute for Molecular Medicine Finland (FIMM), University of Helsinki. The data analysis and normalization was performed using Chipster 3.16.0. Fold change of genes is calculated by arithmetic mean in linear scale and shown in the volcano plot. Fold change &gt;1 (up-regulated gene), fold change &lt; 1 (down-regulated gene). The microarray dataset has been deposited in MIAME-compliant GEO public database as source data. Accession number: GEO accession GSE140884. For quantitative PCR, RNA was isolated individually from whole calvaria and from lambdoid suture of <italic>Rab23<sup>-/-</sup></italic> and Wt embryos at E15.5. 1 µg of RNA from calvarial (n = 3+3) and 500 ng of RNA from lambdoid suture (n = 8+8) were reverse-transcribed into cDNA using random hexamer primer and RevertAid reverse transcriptase (Thermo scientific). 2 µl of diluted cDNA and Brilliant III ultra-fast SYBR-green qPCR master mix with QuantiTect Primers (Qiagen).</p></sec><sec id="s4-4"><title>RNAscope in situ hybridization</title><p>We performed the experiments as previously described (<xref ref-type="bibr" rid="bib57">Sanz-Navarro et al., 2019</xref>). In single-gene in situ RNAscope transcripts appear in red. A customized 20ZZ probe named Mm-<italic>Rab23</italic> targeting 45–1330 of NM_008999.4 was purchased from Advanced Cell Diagnostics to perform <italic>Rab23</italic> expression analysis on mouse calvarial suture. Images were obtained using a bright field microscope (BX61, Olympus).</p></sec><sec id="s4-5"><title>In situ hybridization on whole mounts</title><p>In situ hybridizations on whole embryonic samples was performed using digoxigenin-UTP labeled <italic>Rab23</italic> probe and <italic>Pitx2</italic> probe according to the protocol and modification described (<xref ref-type="bibr" rid="bib28">Kim et al., 1998</xref>).</p></sec><sec id="s4-6"><title>Immunohistochemistry</title><p>Immunohistochemistry on lambdoid sutural samples was performed using primary anti-RAB23, GLI1, RUNX2 and FGFR1 antibody. After incubation with HRP conjugated or alexa fluor conjugated secondary antibody Enzmet detection kit was used for GLI1 and FGFR1 detection and alexa fluor conjugated 488, 546 secondary antibody was used to detect RAB23 and RUNX2 signals. The samples were permeabilized by triton X-100 and antigen retrieval was performed by citrate buffer. All the other procedure was followed according to the protocol described (<xref ref-type="bibr" rid="bib67">Veistinen et al., 2017</xref>).</p></sec><sec id="s4-7"><title>Isolation and culture of mouse calvaria derived primary cells</title><p>WT and <italic>Rab23<sup>-/-</sup></italic> embryos were taken out at E15.5 embryonic day. We and others have previously described the procedure of calvarial primary cells isolation (<xref ref-type="bibr" rid="bib56">Rodan and Noda, 1991</xref>; <xref ref-type="bibr" rid="bib67">Veistinen et al., 2017</xref>). Cells were cultured in DMEM containing high glucose and supplemented with 10% FBS, glutamine, penicillin and streptomycin, maintained at 37°C with 5% CO<sub>2</sub>. After maintaining the isolated cells in growth medium next passage is always used for experiments.</p></sec><sec id="s4-8"><title>Exogenous FGF10 treatment on calvaria derived mesenchymal cells</title><p>E15.5 Wt calvaria derived mesenchymal cells were treated with exogenous FGF10 (250 ng/ml) for 3 hr. <italic>Fgfr1b</italic> and <italic>Fgfr2b</italic> mRNA expression were then assessed by RT-qPCR. E15.5 <italic>Rab23<sup>-/-</sup></italic> calvaria derived mesenchymal cells were treated with exogenous FGF10 (500 ng/ml) for 2 and 4 hr. <italic>Runx2</italic> mRNA expression were then assessed by RT-qPCR.</p></sec><sec id="s4-9"><title>Tissue lysis, protein extraction, quantification and western blotting</title><p>RIPA buffer containing 1% SDS together with protease inhibitor and phosphatase inhibitor were used to lyse the lambdoid sutural tissue on ice. After brief sonication (10 s, twice), tissue lysates were centrifuged at full speed for 10 min to collect the protein supernatant. By using BCA protein assay kit, protein concentrations were measured for immunoblotting analysis. Equal amount of proteins from wild type and RAB23 deficient cells were subjected to prepare to separate on SDS-PAGE under reduced gel electrophoresis (4–20% Mini-PROTEAN TGX Gels, Bio-Rad). After transferring to nitrocellulose membrane, membranes were blocked by odyssey blocking buffer at room temperature for 3 hr. Membranes were then incubated with corresponding primary anti-RAB23, anti-p38, anti-phospho-p38, anti-ERK, anti-pERK, anti-RUNX2, anti-pSMAD1/5/8, anti-GLI1, anti-FGFR1 and anti-Tubulin antibodies and kept overnight at 4°C. Fluorophore-conjugated corresponding IRdye goat anti-rabbit 680LT or CW800 or anti-mouse 800CW secondary antibodies were used at room temperature for 1 hr. α-Tubulin was used to normalize protein expressions. In vitro inhibition of pERK1/2 in <italic>Rab23<sup>-/-</sup></italic> calvaria derived primary cells (E15.5) was performed by adding 5 µM of U0126 and 10 µM of cyclopamine for 6, 24 and 48 hr. Membranes were scanned using an Odyssey infrared imaging system (Odyssey; LI-COR Biosciences, model 9120). Band intensity was determined using ImageJ (NIH) software.</p></sec><sec id="s4-10"><title>Craniosynostosis rescue study and microscopy</title><p>After removing skin and underneath brain calvaria from E18.5 Wt and <italic>Rab23<sup>-/-</sup></italic> were cultured in an in vitro explant culture system. The calvaria was kept on top of the filter laid on metallic grid. The calvaria sample was supplemented with DMEM containing 10% FBS, dexamethasone, ascorbic acid and β-glyceraldehyde. <italic>Rab23<sup>-/-</sup></italic> calvaria received 5 µM of U0126 treatment or DMSO as control. After 48 hr fresh medium and inhibitors were added. After 48 or 72 hr, samples were fixed with 4% PFA for subsequent analysis. For immediate calvarial bone and suture recognition vital bone dye calcein green was injected to mother mouse 1 day before the E17.5 or E18.5 embryo collection. Subsequent imaging in the culture was performed after alizarin red incorporation in the medium. Images were taken by Olympus SZX12 fluorescent microscope.</p></sec><sec id="s4-11"><title>Skeletal staining</title><p>The Alcian blue-Alizarin red staining of E18.5 specimens was performed as previously described (<xref ref-type="bibr" rid="bib51">Rice et al., 2003a</xref>). For analysis of calvarial bone and sutures images were captured using Analysis software (Soft Imaging System) and Olympus BX41 microscope and analyzed in Adobe Photoshop CS4.</p></sec><sec id="s4-12"><title>MEF isolation</title><p>Mouse embryonic fibroblasts (MEFs) were isolated from E13.5 embryos (noon of the vaginal plug detection day was considered E0.5). Briefly, embryos were collected to sterile PBS. The head, liver and spleen were removed and used for histology, RNA isolation or for genotyping. The remaining tissue was cut into smaller pieces and dissociated with gentle pipetting in 0.25% Trypsin-EDTA solution. After 10 min incubation, any larger tissue pieces were discarded and remaining cell suspension was plated with rich MEF medium into two T25 flasks per embryo. The medium was changed daily until first passaging at confluency.</p><p>The growth medium was DMEM, High Glucose, GlutaMAX (Gibco) supplemented with 10% FBS, 1x non-essential amino acids (Gibco), 20 mM Hepes pH 7.3 and 1x penicillin-streptomycin. The cells were subcultured when 90% confluent to 750,000 live cells/T75 flask and only passages 1–6 (active division) were used for EdU pulsed proliferation analyses. The cell density and viability was assessed with Trypan Blue and Countess automated cell counter (Invitrogen).</p></sec><sec id="s4-13"><title>EdU pulsing and staining</title><p>Cell proliferation was assessed by prior EdU incorporation followed by EdU click reaction. The MEF cell lines were pulsed for 1 hr with 10 µM EdU (Molecular probes, Invitrogen) in DMSO dissolved to pre-warmed medium before distribution to cells for 1 hr EdU pulse and fixed with 4% paraformaldehyde. The EdU was detected with Click-iT EdU imaging kit, Alexa fluor 594 (Molecular probes, Invitrogen) according to manufacturer's instruction. The number of EdU positive cells was counted from three separate experiments from a minimum five different locations per cell line and compared to total cell number determined with Hoechst 33342 staining of nuclei.</p><p>The mice were pulsed with 0.05 mg/g (i.p.) EdU in PBS 2 hr collection of tissue. After sacrificing E17.5 embryonic lambdoid sutures were collected and fixed o/n with 4% paraformaldehyde, and processed for paraffin sections. Paraffin-embedded lambdoid sutures were sectioned 7 µm size. The sections were deparaffinized and stained with same Click-iT kit. EdU click reaction procedure in brief, sectional explants were deparaffinized by xylene and rehydrated by a gradient of ethanol series. After washing with 2 mg/ml glycine, sutural sections were permeabilized with 0.5% Triton X-100. After several washing in PBS, 10 µM EdU cocktail was used for click reaction for 30 min at dark room. After several PBS washing 5 µg/ml Hoechst was used for counter staining. Vectashield mounting medium was used to mount the slides. Slides were then imaged with fluorescence microscope with emission wavelength 615 nm.</p><p>Cell counting: Cluster of proliferating cells (red cell) considered as osteogenic front. The middle of the scale was kept on the tip of each osteogenic front and then rest of the part was flanked towards the suture. The length of the scale is 145 µm and width 61 µm. Cells from skin, dura mater and cartilage were not included in counting.</p></sec><sec id="s4-14"><title>Apoptotic assay</title><p>Apoptotic assay on tissue sections from in vitro cultured Wt, control <italic>Rab23<sup>-/-</sup></italic> and U0126 treated <italic>Rab23<sup>-/-</sup></italic> lambdoid suture was performed according to manufacturer protocol (In situ apoptosis detection kit AB206386).</p></sec><sec id="s4-15"><title>X-ray micro computed tomography</title><p>E18.5 WT and <italic>Rab23<sup>-/-</sup></italic> whole head and samples from rescue studies were collected and fixed with 4% paraformaldehyde overnight. Samples were dehydrated by gradient ethanol series to 70% (v/v), followed by processed for x-ray microtomography (µCT) imaging with Bruker SkyScan1272 (desktop micro-CT system, Bruker microCT N.V., Kontich, Belgium). Tomography 3D reconstructions were obtained using the program NRecon (desktop micro-CT system, Bruker microCT N.V., Kontich, Belgium).</p></sec><sec id="s4-16"><title>Data analysis and statistics</title><p>Paired student’s <italic>t-test</italic> has been applied to perform the statistics of all the data obtained from measurements, western blotting and gene expressions. Data represented as mean ± SD. p-Value less than 0.05 considered as statistical significant.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Jonathan Eggenschwiler for providing us <italic>Rab23<sup>opb2</sup></italic> mouse, Pekka Nieminen for his critical and constructive discussion on this project. We also thank Airi Sinkko and Anne Kivimäki for their excellent technical help.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Resources, Software, Formal analysis, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Formal analysis, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Resources, Formal analysis, Validation, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Visualization, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Animal experiments were approved by the University of Helsinki, Helsinki University Hospital and the Southern Finland Council Animal Welfare and Ethics committees. Permit ESAVI/11956/04.10.07/2017 (external) and KEK17-008 (internal).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>List of 223 differentially expressed genes.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-55829-supp1-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-55829-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>MIAME-compliant microarray data has been deposited in GEO database. GEO accession GSE140884 The dataset link: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140884">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140884</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>MR</given-names></name><name><surname>Takatalo</surname><given-names>M</given-names></name><name><surname>Rice</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Microarray based gene expression analysis in Wt and Rab23-/- mice calvaria at embryonic day 15.5</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140884">GSE140884</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Alam</surname> <given-names>D</given-names></name><name><surname>Sala</surname> <given-names>FG</given-names></name><name><surname>Baptista</surname> <given-names>S</given-names></name><name><surname>Galzote</surname> <given-names>R</given-names></name><name><surname>Danopoulos</surname> <given-names>S</given-names></name><name><surname>Tiozzo</surname> <given-names>C</given-names></name><name><surname>Gage</surname> <given-names>P</given-names></name><name><surname>Grikscheit</surname> <given-names>T</given-names></name><name><surname>Warburton</surname> <given-names>D</given-names></name><name><surname>Frey</surname> <given-names>MR</given-names></name><name><surname>Bellusci</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>FGF9-Pitx2-FGF10 signaling controls cecal formation in mice</article-title><source>Developmental Biology</source><volume>369</volume><fpage>340</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2012.07.008</pub-id><pub-id pub-id-type="pmid">22819677</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Alam</surname> <given-names>D</given-names></name><name><surname>El Agha</surname> <given-names>E</given-names></name><name><surname>Sakurai</surname> <given-names>R</given-names></name><name><surname>Kheirollahi</surname> <given-names>V</given-names></name><name><surname>Moiseenko</surname> <given-names>A</given-names></name><name><surname>Danopoulos</surname> <given-names>S</given-names></name><name><surname>Shrestha</surname> <given-names>A</given-names></name><name><surname>Schmoldt</surname> <given-names>C</given-names></name><name><surname>Quantius</surname> <given-names>J</given-names></name><name><surname>Herold</surname> <given-names>S</given-names></name><name><surname>Chao</surname> <given-names>CM</given-names></name><name><surname>Tiozzo</surname> <given-names>C</given-names></name><name><surname>De Langhe</surname> <given-names>S</given-names></name><name><surname>Plikus</surname> <given-names>MV</given-names></name><name><surname>Thornton</surname> <given-names>M</given-names></name><name><surname>Grubbs</surname> <given-names>B</given-names></name><name><surname>Minoo</surname> <given-names>P</given-names></name><name><surname>Rehan</surname> <given-names>VK</given-names></name><name><surname>Bellusci</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Evidence for the involvement of fibroblast growth factor 10 in lipofibroblast formation during embryonic lung development</article-title><source>Development</source><volume>142</volume><fpage>4139</fpage><lpage>4150</lpage><pub-id pub-id-type="doi">10.1242/dev.109173</pub-id><pub-id pub-id-type="pmid">26511927</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bochukova</surname> <given-names>EG</given-names></name><name><surname>Roscioli</surname> <given-names>T</given-names></name><name><surname>Hedges</surname> <given-names>DJ</given-names></name><name><surname>Taylor</surname> <given-names>IB</given-names></name><name><surname>Johnson</surname> <given-names>D</given-names></name><name><surname>David</surname> <given-names>DJ</given-names></name><name><surname>Deininger</surname> <given-names>PL</given-names></name><name><surname>Wilkie</surname> <given-names>AO</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Rare mutations of <italic>FGFR2</italic> causing apert syndrome: identification of the first partial gene deletion, and an <italic>alu</italic> element insertion from a new subfamily</article-title><source>Human Mutation</source><volume>30</volume><fpage>204</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1002/humu.20825</pub-id><pub-id pub-id-type="pmid">18726952</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpenter</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="1909">1909</year><article-title>Acrocephaly, with other congenital malformations</article-title><source>Proceedings of the Royal Society of Medicine</source><volume>2</volume><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1177/003591570900201418</pub-id><pub-id pub-id-type="pmid">19974019</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname> <given-names>S</given-names></name><name><surname>Xie</surname> <given-names>G</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Chen</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Xie</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Rab23 negatively regulates Gli1 transcriptional factor in a su(Fu)-dependent manner</article-title><source>Cellular Signalling</source><volume>24</volume><fpage>1222</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2012.02.004</pub-id><pub-id pub-id-type="pmid">22365972</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>SC</given-names></name><name><surname>Kim</surname> <given-names>SJ</given-names></name><name><surname>Choi</surname> <given-names>JH</given-names></name><name><surname>Park</surname> <given-names>CY</given-names></name><name><surname>Shim</surname> <given-names>WJ</given-names></name><name><surname>Lim</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways</article-title><source>Stem Cells and Development</source><volume>17</volume><fpage>725</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1089/scd.2007.0230</pub-id><pub-id pub-id-type="pmid">18788932</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debiais</surname> <given-names>F</given-names></name><name><surname>Hott</surname> <given-names>M</given-names></name><name><surname>Graulet</surname> <given-names>AM</given-names></name><name><surname>Marie</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The effects of fibroblast growth factor-2 on human neonatal calvaria osteoblastic cells are differentiation stage specific</article-title><source>Journal of Bone and Mineral Research</source><volume>13</volume><fpage>645</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1359/jbmr.1998.13.4.645</pub-id><pub-id pub-id-type="pmid">9556064</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggenschwiler</surname> <given-names>JT</given-names></name><name><surname>Espinoza</surname> <given-names>E</given-names></name><name><surname>Anderson</surname> <given-names>KV</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Rab23 is an essential negative regulator of the mouse sonic hedgehog signalling pathway</article-title><source>Nature</source><volume>412</volume><fpage>194</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1038/35084089</pub-id><pub-id pub-id-type="pmid">11449277</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggenschwiler</surname> <given-names>JT</given-names></name><name><surname>Bulgakov</surname> <given-names>OV</given-names></name><name><surname>Qin</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>T</given-names></name><name><surname>Anderson</surname> <given-names>KV</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mouse Rab23 regulates hedgehog signaling from smoothened to gli proteins</article-title><source>Developmental Biology</source><volume>290</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2005.09.022</pub-id><pub-id pub-id-type="pmid">16364285</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggenschwiler</surname> <given-names>JT</given-names></name><name><surname>Anderson</surname> <given-names>KV</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Dorsal and lateral fates in the mouse neural tube require the cell-autonomous activity of the open brain gene</article-title><source>Developmental Biology</source><volume>227</volume><fpage>648</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1006/dbio.2000.9918</pub-id><pub-id pub-id-type="pmid">11071781</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname> <given-names>TM</given-names></name><name><surname>Ferguson</surname> <given-names>C</given-names></name><name><surname>Wainwright</surname> <given-names>BJ</given-names></name><name><surname>Parton</surname> <given-names>RG</given-names></name><name><surname>Wicking</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Rab23, a negative regulator of hedgehog signaling, localizes to the plasma membrane and the endocytic pathway</article-title><source>Traffic</source><volume>4</volume><fpage>869</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1046/j.1600-0854.2003.00141.x</pub-id><pub-id pub-id-type="pmid">14617350</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franceschi</surname> <given-names>RT</given-names></name><name><surname>Ge</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Control of the osteoblast lineage by Mitogen-Activated protein kinase signaling</article-title><source>Current Molecular Biology Reports</source><volume>3</volume><fpage>122</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1007/s40610-017-0059-5</pub-id><pub-id pub-id-type="pmid">29057206</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuller</surname> <given-names>K</given-names></name><name><surname>O'Connell</surname> <given-names>JT</given-names></name><name><surname>Gordon</surname> <given-names>J</given-names></name><name><surname>Mauti</surname> <given-names>O</given-names></name><name><surname>Eggenschwiler</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rab23 regulates nodal signaling in vertebrate left-right patterning independently of the hedgehog pathway</article-title><source>Developmental Biology</source><volume>391</volume><fpage>182</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2014.04.012</pub-id><pub-id pub-id-type="pmid">24780629</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname> <given-names>C</given-names></name><name><surname>Yang</surname> <given-names>Q</given-names></name><name><surname>Zhao</surname> <given-names>G</given-names></name><name><surname>Yu</surname> <given-names>H</given-names></name><name><surname>Kirkwood</surname> <given-names>KL</given-names></name><name><surname>Franceschi</surname> <given-names>RT</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Interactions between extracellular signal-regulated kinase 1/2 and p38 MAP kinase pathways in the control of RUNX2 phosphorylation and transcriptional activity</article-title><source>Journal of Bone and Mineral Research</source><volume>27</volume><fpage>538</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1002/jbmr.561</pub-id><pub-id pub-id-type="pmid">22072425</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goos</surname> <given-names>JAC</given-names></name><name><surname>Mathijssen</surname> <given-names>IMJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genetic causes of craniosynostosis: an update</article-title><source>Molecular Syndromology</source><volume>10</volume><fpage>6</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1159/000492266</pub-id><pub-id pub-id-type="pmid">30976276</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Günther</surname> <given-names>T</given-names></name><name><surname>Struwe</surname> <given-names>M</given-names></name><name><surname>Aguzzi</surname> <given-names>A</given-names></name><name><surname>Schughart</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Open brain, a new mouse mutant with severe neural tube defects, shows altered gene expression patterns in the developing spinal cord</article-title><source>Development</source><volume>120</volume><fpage>3119</fpage><lpage>3130</lpage><pub-id pub-id-type="pmid">7720556</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajihosseini</surname> <given-names>MK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Fibroblast growth factor signaling in cranial suture development and pathogenesis</article-title><source>Frontiers of Oral Biology</source><volume>12</volume><fpage>160</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1159/000115037</pub-id><pub-id pub-id-type="pmid">18391500</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajihosseini</surname> <given-names>MK</given-names></name><name><surname>Duarte</surname> <given-names>R</given-names></name><name><surname>Pegrum</surname> <given-names>J</given-names></name><name><surname>Donjacour</surname> <given-names>A</given-names></name><name><surname>Lana-Elola</surname> <given-names>E</given-names></name><name><surname>Rice</surname> <given-names>DP</given-names></name><name><surname>Sharpe</surname> <given-names>J</given-names></name><name><surname>Dickson</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Evidence that Fgf10 contributes to the skeletal and visceral defects of an apert syndrome mouse model</article-title><source>Developmental Dynamics</source><volume>238</volume><fpage>376</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1002/dvdy.21648</pub-id><pub-id pub-id-type="pmid">18773495</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hor</surname> <given-names>CHH</given-names></name><name><surname>Goh</surname> <given-names>ELK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rab23 regulates radial migration of projection neurons via N-cadherin</article-title><source>Cerebral Cortex</source><volume>28</volume><fpage>1516</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhy018</pub-id><pub-id pub-id-type="pmid">29420702</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname> <given-names>JA</given-names></name><name><surname>Jenkins</surname> <given-names>D</given-names></name><name><surname>Vasudevan</surname> <given-names>PC</given-names></name><name><surname>Kirchhoff</surname> <given-names>M</given-names></name><name><surname>Skovby</surname> <given-names>F</given-names></name><name><surname>Rieubland</surname> <given-names>C</given-names></name><name><surname>Gallati</surname> <given-names>S</given-names></name><name><surname>Rittinger</surname> <given-names>O</given-names></name><name><surname>Kroisel</surname> <given-names>PM</given-names></name><name><surname>Johnson</surname> <given-names>D</given-names></name><name><surname>Biesecker</surname> <given-names>LG</given-names></name><name><surname>Wilkie</surname> <given-names>AO</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Metopic and sagittal synostosis in Greig cephalopolysyndactyly syndrome: five cases with intragenic mutations or complete deletions of GLI3</article-title><source>European Journal of Human Genetics</source><volume>19</volume><fpage>757</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2011.13</pub-id><pub-id pub-id-type="pmid">21326280</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahimi</surname> <given-names>OA</given-names></name><name><surname>Eliseenkova</surname> <given-names>AV</given-names></name><name><surname>Plotnikov</surname> <given-names>AN</given-names></name><name><surname>Yu</surname> <given-names>K</given-names></name><name><surname>Ornitz</surname> <given-names>DM</given-names></name><name><surname>Mohammadi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Structural basis for fibroblast growth factor receptor 2 activation in apert syndrome</article-title><source>PNAS</source><volume>98</volume><fpage>7182</fpage><lpage>7187</lpage><pub-id pub-id-type="doi">10.1073/pnas.121183798</pub-id><pub-id pub-id-type="pmid">11390973</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahimi</surname> <given-names>OA</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name><name><surname>Eliseenkova</surname> <given-names>AV</given-names></name><name><surname>Itoh</surname> <given-names>N</given-names></name><name><surname>Linhardt</surname> <given-names>RJ</given-names></name><name><surname>Mohammadi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities</article-title><source>Human Molecular Genetics</source><volume>13</volume><fpage>2313</fpage><lpage>2324</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddh235</pub-id><pub-id pub-id-type="pmid">15282208</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname> <given-names>D</given-names></name><name><surname>Seelow</surname> <given-names>D</given-names></name><name><surname>Jehee</surname> <given-names>FS</given-names></name><name><surname>Perlyn</surname> <given-names>CA</given-names></name><name><surname>Alonso</surname> <given-names>LG</given-names></name><name><surname>Bueno</surname> <given-names>DF</given-names></name><name><surname>Donnai</surname> <given-names>D</given-names></name><name><surname>Josifova</surname> <given-names>D</given-names></name><name><surname>Josifiova</surname> <given-names>D</given-names></name><name><surname>Mathijssen</surname> <given-names>IM</given-names></name><name><surname>Morton</surname> <given-names>JE</given-names></name><name><surname>Orstavik</surname> <given-names>KH</given-names></name><name><surname>Sweeney</surname> <given-names>E</given-names></name><name><surname>Wall</surname> <given-names>SA</given-names></name><name><surname>Marsh</surname> <given-names>JL</given-names></name><name><surname>Nurnberg</surname> <given-names>P</given-names></name><name><surname>Passos-Bueno</surname> <given-names>MR</given-names></name><name><surname>Wilkie</surname> <given-names>AO</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>RAB23 mutations in carpenter syndrome imply an unexpected role for hedgehog signaling in cranial-suture development and obesity</article-title><source>The American Journal of Human Genetics</source><volume>80</volume><fpage>1162</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1086/518047</pub-id><pub-id pub-id-type="pmid">17503333</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname> <given-names>D</given-names></name><name><surname>Baynam</surname> <given-names>G</given-names></name><name><surname>De Catte</surname> <given-names>L</given-names></name><name><surname>Elcioglu</surname> <given-names>N</given-names></name><name><surname>Gabbett</surname> <given-names>MT</given-names></name><name><surname>Hudgins</surname> <given-names>L</given-names></name><name><surname>Hurst</surname> <given-names>JA</given-names></name><name><surname>Jehee</surname> <given-names>FS</given-names></name><name><surname>Oley</surname> <given-names>C</given-names></name><name><surname>Wilkie</surname> <given-names>AO</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Carpenter syndrome: extended <italic>RAB23</italic> mutation spectrum and analysis of nonsense-mediated mRNA decay</article-title><source>Human Mutation</source><volume>32</volume><fpage>E2069</fpage><lpage>E2078</lpage><pub-id pub-id-type="doi">10.1002/humu.21457</pub-id><pub-id pub-id-type="pmid">21412941</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>D</given-names></name><name><surname>Wilkie</surname> <given-names>AO</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Craniosynostosis</article-title><source>European Journal of Human Genetics</source><volume>19</volume><fpage>369</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2010.235</pub-id><pub-id pub-id-type="pmid">21248745</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalff-Suske</surname> <given-names>M</given-names></name><name><surname>Wild</surname> <given-names>A</given-names></name><name><surname>Topp</surname> <given-names>J</given-names></name><name><surname>Wessling</surname> <given-names>M</given-names></name><name><surname>Jacobsen</surname> <given-names>EM</given-names></name><name><surname>Bornholdt</surname> <given-names>D</given-names></name><name><surname>Engel</surname> <given-names>H</given-names></name><name><surname>Heuer</surname> <given-names>H</given-names></name><name><surname>Aalfs</surname> <given-names>CM</given-names></name><name><surname>Ausems</surname> <given-names>MG</given-names></name><name><surname>Barone</surname> <given-names>R</given-names></name><name><surname>Herzog</surname> <given-names>A</given-names></name><name><surname>Heutink</surname> <given-names>P</given-names></name><name><surname>Homfray</surname> <given-names>T</given-names></name><name><surname>Gillessen-Kaesbach</surname> <given-names>G</given-names></name><name><surname>König</surname> <given-names>R</given-names></name><name><surname>Kunze</surname> <given-names>J</given-names></name><name><surname>Meinecke</surname> <given-names>P</given-names></name><name><surname>Müller</surname> <given-names>D</given-names></name><name><surname>Rizzo</surname> <given-names>R</given-names></name><name><surname>Strenge</surname> <given-names>S</given-names></name><name><surname>Superti-Furga</surname> <given-names>A</given-names></name><name><surname>Grzeschik</surname> <given-names>KH</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Point mutations throughout the GLI3 gene cause Greig cephalopolysyndactyly syndrome</article-title><source>Human Molecular Genetics</source><volume>8</volume><fpage>1769</fpage><lpage>1777</lpage><pub-id pub-id-type="doi">10.1093/hmg/8.9.1769</pub-id><pub-id pub-id-type="pmid">10441342</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasarskis</surname> <given-names>A</given-names></name><name><surname>Manova</surname> <given-names>K</given-names></name><name><surname>Anderson</surname> <given-names>KV</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A phenotype-based screen for embryonic lethal mutations in the mouse</article-title><source>PNAS</source><volume>95</volume><fpage>7485</fpage><lpage>7490</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.13.7485</pub-id><pub-id pub-id-type="pmid">9636176</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>HJ</given-names></name><name><surname>Rice</surname> <given-names>DP</given-names></name><name><surname>Kettunen</surname> <given-names>PJ</given-names></name><name><surname>Thesleff</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>FGF-, BMP- and shh-mediated signalling pathways in the regulation of cranial suture morphogenesis and calvarial bone development</article-title><source>Development</source><volume>125</volume><fpage>1241</fpage><lpage>1251</lpage><pub-id pub-id-type="pmid">9477322</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komatsu</surname> <given-names>Y</given-names></name><name><surname>Yu</surname> <given-names>PB</given-names></name><name><surname>Kamiya</surname> <given-names>N</given-names></name><name><surname>Pan</surname> <given-names>H</given-names></name><name><surname>Fukuda</surname> <given-names>T</given-names></name><name><surname>Scott</surname> <given-names>GJ</given-names></name><name><surname>Ray</surname> <given-names>MK</given-names></name><name><surname>Yamamura</surname> <given-names>K</given-names></name><name><surname>Mishina</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Augmentation of Smad-dependent BMP signaling in neural crest cells causes craniosynostosis in mice</article-title><source>Journal of Bone and Mineral Research</source><volume>28</volume><fpage>1422</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1002/jbmr.1857</pub-id><pub-id pub-id-type="pmid">23281127</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyono</surname> <given-names>A</given-names></name><name><surname>Avishai</surname> <given-names>N</given-names></name><name><surname>Ouyang</surname> <given-names>Z</given-names></name><name><surname>Landreth</surname> <given-names>GE</given-names></name><name><surname>Murakami</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiation</article-title><source>Journal of Bone and Mineral Metabolism</source><volume>30</volume><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s00774-011-0288-2</pub-id><pub-id pub-id-type="pmid">21678127</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lana-Elola</surname> <given-names>E</given-names></name><name><surname>Rice</surname> <given-names>R</given-names></name><name><surname>Grigoriadis</surname> <given-names>AE</given-names></name><name><surname>Rice</surname> <given-names>DP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Cell fate specification during calvarial bone and suture development</article-title><source>Developmental Biology</source><volume>311</volume><fpage>335</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2007.08.028</pub-id><pub-id pub-id-type="pmid">17931618</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langemeyer</surname> <given-names>L</given-names></name><name><surname>Fröhlich</surname> <given-names>F</given-names></name><name><surname>Ungermann</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Rab GTPase function in Endosome and lysosome biogenesis</article-title><source>Trends in Cell Biology</source><volume>28</volume><fpage>957</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2018.06.007</pub-id><pub-id pub-id-type="pmid">30025982</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leaf</surname> <given-names>A</given-names></name><name><surname>Von Zastrow</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dopamine receptors reveal an essential role of IFT-B, KIF17, and Rab23 in delivering specific receptors to primary cilia</article-title><source>eLife</source><volume>4</volume><elocation-id>06996</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.06996</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>JM</given-names></name><name><surname>Kim</surname> <given-names>JY</given-names></name><name><surname>Cho</surname> <given-names>KW</given-names></name><name><surname>Lee</surname> <given-names>MJ</given-names></name><name><surname>Cho</surname> <given-names>SW</given-names></name><name><surname>Kwak</surname> <given-names>S</given-names></name><name><surname>Cai</surname> <given-names>J</given-names></name><name><surname>Jung</surname> <given-names>HS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Wnt11/Fgfr1b cross-talk modulates the fate of cells in palate development</article-title><source>Developmental Biology</source><volume>314</volume><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2007.11.033</pub-id><pub-id pub-id-type="pmid">18191119</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>E</given-names></name><name><surname>Le</surname> <given-names>T</given-names></name><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Elakis</surname> <given-names>G</given-names></name><name><surname>Turner</surname> <given-names>A</given-names></name><name><surname>Lo</surname> <given-names>W</given-names></name><name><surname>Venselaar</surname> <given-names>H</given-names></name><name><surname>Verrenkamp</surname> <given-names>CA</given-names></name><name><surname>Snow</surname> <given-names>N</given-names></name><name><surname>Mowat</surname> <given-names>D</given-names></name><name><surname>Kirk</surname> <given-names>EP</given-names></name><name><surname>Sachdev</surname> <given-names>R</given-names></name><name><surname>Smith</surname> <given-names>J</given-names></name><name><surname>Brown</surname> <given-names>NJ</given-names></name><name><surname>Wallis</surname> <given-names>M</given-names></name><name><surname>Barnett</surname> <given-names>C</given-names></name><name><surname>McKenzie</surname> <given-names>F</given-names></name><name><surname>Freckmann</surname> <given-names>ML</given-names></name><name><surname>Collins</surname> <given-names>F</given-names></name><name><surname>Chopra</surname> <given-names>M</given-names></name><name><surname>Gregersen</surname> <given-names>N</given-names></name><name><surname>Hayes</surname> <given-names>I</given-names></name><name><surname>Rajagopalan</surname> <given-names>S</given-names></name><name><surname>Tan</surname> <given-names>TY</given-names></name><name><surname>Stark</surname> <given-names>Z</given-names></name><name><surname>Savarirayan</surname> <given-names>R</given-names></name><name><surname>Yeung</surname> <given-names>A</given-names></name><name><surname>Adès</surname> <given-names>L</given-names></name><name><surname>Gattas</surname> <given-names>M</given-names></name><name><surname>Gibson</surname> <given-names>K</given-names></name><name><surname>Gabbett</surname> <given-names>M</given-names></name><name><surname>Amor</surname> <given-names>DJ</given-names></name><name><surname>Lattanzi</surname> <given-names>W</given-names></name><name><surname>Boyd</surname> <given-names>S</given-names></name><name><surname>Haan</surname> <given-names>E</given-names></name><name><surname>Gianoutsos</surname> <given-names>M</given-names></name><name><surname>Cox</surname> <given-names>TC</given-names></name><name><surname>Buckley</surname> <given-names>MF</given-names></name><name><surname>Roscioli</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>A craniosynostosis massively parallel sequencing panel study in 309 australian and New Zealand patients: findings and recommendations</article-title><source>Genetics in Medicine</source><volume>20</volume><fpage>1061</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1038/gim.2017.214</pub-id><pub-id pub-id-type="pmid">29215649</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>KKL</given-names></name><name><surname>Peskett</surname> <given-names>E</given-names></name><name><surname>Quinn</surname> <given-names>CM</given-names></name><name><surname>Aiello</surname> <given-names>R</given-names></name><name><surname>Adeeva</surname> <given-names>L</given-names></name><name><surname>Moulding</surname> <given-names>DA</given-names></name><name><surname>Stanier</surname> <given-names>P</given-names></name><name><surname>Pauws</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>Overexpression of <italic>Fgfr2c</italic> causes craniofacial bone hypoplasia and ameliorates craniosynostosis in the crouzon mouse</article-title><source>Disease Models &amp; Mechanisms</source><volume>11</volume><elocation-id>dmm035311</elocation-id><pub-id pub-id-type="doi">10.1242/dmm.035311</pub-id><pub-id pub-id-type="pmid">30266836</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenton</surname> <given-names>K</given-names></name><name><surname>James</surname> <given-names>AW</given-names></name><name><surname>Manu</surname> <given-names>A</given-names></name><name><surname>Brugmann</surname> <given-names>SA</given-names></name><name><surname>Birker</surname> <given-names>D</given-names></name><name><surname>Nelson</surname> <given-names>ER</given-names></name><name><surname>Leucht</surname> <given-names>P</given-names></name><name><surname>Helms</surname> <given-names>JA</given-names></name><name><surname>Longaker</surname> <given-names>MT</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Indian hedgehog positively regulates calvarial ossification and modulates bone morphogenetic protein signaling</article-title><source>Genesis</source><volume>49</volume><fpage>784</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1002/dvg.20768</pub-id><pub-id pub-id-type="pmid">21557453</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname> <given-names>YS</given-names></name><name><surname>Tang</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A role for Rab23 in the trafficking of Kif17 to the primary cilium</article-title><source>Journal of Cell Science</source><volume>128</volume><fpage>2996</fpage><lpage>3008</lpage><pub-id pub-id-type="doi">10.1242/jcs.163964</pub-id><pub-id pub-id-type="pmid">26136363</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>N</given-names></name><name><surname>Teng</surname> <given-names>X</given-names></name><name><surname>Zheng</surname> <given-names>Q</given-names></name><name><surname>Chen</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The regulatory mechanism of p38/MAPK in the chondrogenic differentiation from bone marrow mesenchymal stem cells</article-title><source>Journal of Orthopaedic Surgery and Research</source><volume>14</volume><elocation-id>434</elocation-id><pub-id pub-id-type="doi">10.1186/s13018-019-1505-2</pub-id><pub-id pub-id-type="pmid">31831024</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Polydactyly: phenotypes, genetics and classification</article-title><source>Clinical Genetics</source><volume>85</volume><fpage>203</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1111/cge.12276</pub-id><pub-id pub-id-type="pmid">24020795</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantilla-Capacho</surname> <given-names>JM</given-names></name><name><surname>Arnaud</surname> <given-names>L</given-names></name><name><surname>Díaz-Rodriguez</surname> <given-names>M</given-names></name><name><surname>Barros-Núñez</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Apert syndrome with preaxial polydactyly showing the typical mutation Ser252Trp in the FGFR2 gene</article-title><source>Genetic Counseling</source><volume>16</volume><fpage>403</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">16440883</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishioka</surname> <given-names>C</given-names></name><name><surname>Ikezoe</surname> <given-names>T</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Yokoyama</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene</article-title><source>Leukemia</source><volume>24</volume><fpage>1631</fpage><lpage>1640</lpage><pub-id pub-id-type="doi">10.1038/leu.2010.145</pub-id><pub-id pub-id-type="pmid">20596030</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname> <given-names>CD</given-names></name><name><surname>Chang</surname> <given-names>SH</given-names></name><name><surname>Yoon</surname> <given-names>YM</given-names></name><name><surname>Lee</surname> <given-names>SJ</given-names></name><name><surname>Lee</surname> <given-names>YS</given-names></name><name><surname>Kang</surname> <given-names>SS</given-names></name><name><surname>Chun</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Opposing role of Mitogen-activated protein kinase subtypes, Erk-1/2 and p38, in the regulation of chondrogenesis of mesenchymes</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>5613</fpage><lpage>5619</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.8.5613</pub-id><pub-id pub-id-type="pmid">10681543</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldridge</surname> <given-names>M</given-names></name><name><surname>Zackai</surname> <given-names>EH</given-names></name><name><surname>McDonald-McGinn</surname> <given-names>DM</given-names></name><name><surname>Iseki</surname> <given-names>S</given-names></name><name><surname>Morriss-Kay</surname> <given-names>GM</given-names></name><name><surname>Twigg</surname> <given-names>SR</given-names></name><name><surname>Johnson</surname> <given-names>D</given-names></name><name><surname>Wall</surname> <given-names>SA</given-names></name><name><surname>Jiang</surname> <given-names>W</given-names></name><name><surname>Theda</surname> <given-names>C</given-names></name><name><surname>Jabs</surname> <given-names>EW</given-names></name><name><surname>Wilkie</surname> <given-names>AO</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>De novo alu-element insertions in FGFR2 identify a distinct pathological basis for apert syndrome</article-title><source>The American Journal of Human Genetics</source><volume>64</volume><fpage>446</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1086/302245</pub-id><pub-id pub-id-type="pmid">9973282</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olkkonen</surname> <given-names>VM</given-names></name><name><surname>Peterson</surname> <given-names>JR</given-names></name><name><surname>Dupree</surname> <given-names>P</given-names></name><name><surname>Lütcke</surname> <given-names>A</given-names></name><name><surname>Zerial</surname> <given-names>M</given-names></name><name><surname>Simons</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Isolation of a mouse cDNA encoding Rab23, a small novel GTPase expressed predominantly in the brain</article-title><source>Gene</source><volume>138</volume><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(94)90809-5</pub-id><pub-id pub-id-type="pmid">8125302</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ornitz</surname> <given-names>DM</given-names></name><name><surname>Itoh</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The fibroblast growth factor signaling pathway</article-title><source>Wiley Interdisciplinary Reviews: Developmental Biology</source><volume>4</volume><fpage>215</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1002/wdev.176</pub-id><pub-id pub-id-type="pmid">25772309</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Abraham</surname> <given-names>P</given-names></name><name><surname>Komatsu</surname> <given-names>Y</given-names></name><name><surname>Lyons</surname> <given-names>K</given-names></name><name><surname>Kaartinen</surname> <given-names>V</given-names></name><name><surname>Mishina</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>BmpR1A is a major type 1 BMP receptor for BMP-Smad signaling during skull development</article-title><source>Developmental Biology</source><volume>429</volume><fpage>260</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2017.06.020</pub-id><pub-id pub-id-type="pmid">28641928</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaff</surname> <given-names>MJ</given-names></name><name><surname>Xue</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Horowitz</surname> <given-names>MC</given-names></name><name><surname>Steinbacher</surname> <given-names>DM</given-names></name><name><surname>Eswarakumar</surname> <given-names>JVP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>FGFR2c-mediated ERK-MAPK activity regulates coronal suture development</article-title><source>Developmental Biology</source><volume>415</volume><fpage>242</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2016.03.026</pub-id><pub-id pub-id-type="pmid">27034231</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietrobono</surname> <given-names>S</given-names></name><name><surname>Gagliardi</surname> <given-names>S</given-names></name><name><surname>Stecca</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Non-canonical hedgehog signaling pathway in Cancer: activation of GLI transcription factors beyond smoothened</article-title><source>Frontiers in Genetics</source><volume>10</volume><elocation-id>556</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2019.00556</pub-id><pub-id pub-id-type="pmid">31244888</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname> <given-names>X</given-names></name><name><surname>Jiang</surname> <given-names>Q</given-names></name><name><surname>Miyazaki</surname> <given-names>T</given-names></name><name><surname>Komori</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Runx2 regulates cranial suture closure by inducing hedgehog, fgf, wnt and pthlh signaling pathway gene expressions in suture mesenchymal cells</article-title><source>Human Molecular Genetics</source><volume>28</volume><fpage>896</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy386</pub-id><pub-id pub-id-type="pmid">30445456</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname> <given-names>DP</given-names></name><name><surname>Rice</surname> <given-names>R</given-names></name><name><surname>Thesleff</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2003">2003a</year><article-title>Molecular mechanisms in calvarial bone and suture development, and their relation to craniosynostosis</article-title><source>The European Journal of Orthodontics</source><volume>25</volume><fpage>139</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1093/ejo/25.2.139</pub-id><pub-id pub-id-type="pmid">12737212</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname> <given-names>R</given-names></name><name><surname>Rice</surname> <given-names>DP</given-names></name><name><surname>Olsen</surname> <given-names>BR</given-names></name><name><surname>Thesleff</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2003">2003b</year><article-title>Progression of calvarial bone development requires Foxc1 regulation of Msx2 and Alx4</article-title><source>Developmental Biology</source><volume>262</volume><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/S0012-1606(03)00355-5</pub-id><pub-id pub-id-type="pmid">14512019</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname> <given-names>R</given-names></name><name><surname>Spencer-Dene</surname> <given-names>B</given-names></name><name><surname>Connor</surname> <given-names>EC</given-names></name><name><surname>Gritli-Linde</surname> <given-names>A</given-names></name><name><surname>McMahon</surname> <given-names>AP</given-names></name><name><surname>Dickson</surname> <given-names>C</given-names></name><name><surname>Thesleff</surname> <given-names>I</given-names></name><name><surname>Rice</surname> <given-names>DP</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Disruption of Fgf10/Fgfr2b-coordinated epithelial-mesenchymal interactions causes cleft palate</article-title><source>Journal of Clinical Investigation</source><volume>113</volume><fpage>1692</fpage><lpage>1700</lpage><pub-id pub-id-type="doi">10.1172/JCI20384</pub-id><pub-id pub-id-type="pmid">15199404</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname> <given-names>DP</given-names></name><name><surname>Connor</surname> <given-names>EC</given-names></name><name><surname>Veltmaat</surname> <given-names>JM</given-names></name><name><surname>Lana-Elola</surname> <given-names>E</given-names></name><name><surname>Veistinen</surname> <given-names>L</given-names></name><name><surname>Tanimoto</surname> <given-names>Y</given-names></name><name><surname>Bellusci</surname> <given-names>S</given-names></name><name><surname>Rice</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Gli3Xt-J/Xt-J mice exhibit lambdoid suture craniosynostosis which results from altered osteoprogenitor proliferation and differentiation</article-title><source>Human Molecular Genetics</source><volume>19</volume><fpage>3457</fpage><lpage>3467</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddq258</pub-id><pub-id pub-id-type="pmid">20570969</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname> <given-names>DP</given-names></name><name><surname>Rice</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Locate, condense, differentiate, grow and confront: developmental mechanisms controlling intramembranous bone and suture formation and function</article-title><source>Frontiers of Oral Biology</source><volume>12</volume><fpage>22</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1159/000115030</pub-id><pub-id pub-id-type="pmid">18391493</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodan</surname> <given-names>GA</given-names></name><name><surname>Noda</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Gene expression in Osteoblastic cells</article-title><source>Critical Reviews in Eukaryotic Gene Expression</source><volume>1</volume><fpage>85</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">1802105</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanz-Navarro</surname> <given-names>M</given-names></name><name><surname>Delgado</surname> <given-names>I</given-names></name><name><surname>Torres</surname> <given-names>M</given-names></name><name><surname>Mustonen</surname> <given-names>T</given-names></name><name><surname>Michon</surname> <given-names>F</given-names></name><name><surname>Rice</surname> <given-names>DP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dental epithelial stem cells express the developmental regulator <italic>Meis1</italic></article-title><source>Frontiers in Physiology</source><volume>10</volume><elocation-id>249</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2019.00249</pub-id><pub-id pub-id-type="pmid">30914971</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanton</surname> <given-names>LA</given-names></name><name><surname>Underhill</surname> <given-names>TM</given-names></name><name><surname>Beier</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>MAP kinases in chondrocyte differentiation</article-title><source>Developmental Biology</source><volume>263</volume><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/S0012-1606(03)00321-X</pub-id><pub-id pub-id-type="pmid">14597193</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timberlake</surname> <given-names>AT</given-names></name><name><surname>Furey</surname> <given-names>CG</given-names></name><name><surname>Choi</surname> <given-names>J</given-names></name><name><surname>Nelson-Williams</surname> <given-names>C</given-names></name><name><surname>Loring</surname> <given-names>E</given-names></name><name><surname>Galm</surname> <given-names>A</given-names></name><name><surname>Kahle</surname> <given-names>KT</given-names></name><name><surname>Steinbacher</surname> <given-names>DM</given-names></name><name><surname>Larysz</surname> <given-names>D</given-names></name><name><surname>Persing</surname> <given-names>JA</given-names></name><name><surname>Lifton</surname> <given-names>RP</given-names></name><collab>Yale Center for Genome Analysis</collab></person-group><year iso-8601-date="2017">2017</year><article-title>De novo mutations in inhibitors of wnt, BMP, and ras/ERK signaling pathways in non-syndromic midline craniosynostosis</article-title><source>PNAS</source><volume>114</volume><fpage>E7341</fpage><lpage>E7347</lpage><pub-id pub-id-type="doi">10.1073/pnas.1709255114</pub-id><pub-id pub-id-type="pmid">28808027</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topczewska</surname> <given-names>JM</given-names></name><name><surname>Shoela</surname> <given-names>RA</given-names></name><name><surname>Tomaszewski</surname> <given-names>JP</given-names></name><name><surname>Mirmira</surname> <given-names>RB</given-names></name><name><surname>Gosain</surname> <given-names>AK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The morphogenesis of cranial sutures in zebrafish</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0165775</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0165775</pub-id><pub-id pub-id-type="pmid">27829009</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twigg</surname> <given-names>SRF</given-names></name><name><surname>Vorgia</surname> <given-names>E</given-names></name><name><surname>McGowan</surname> <given-names>SJ</given-names></name><name><surname>Peraki</surname> <given-names>I</given-names></name><name><surname>Fenwick</surname> <given-names>AL</given-names></name><name><surname>Sharma</surname> <given-names>VP</given-names></name><name><surname>Allegra</surname> <given-names>M</given-names></name><name><surname>Zaragkoulias</surname> <given-names>A</given-names></name><name><surname>Akha</surname> <given-names>ES</given-names></name><name><surname>Knight</surname> <given-names>SJL</given-names></name><name><surname>Lord</surname> <given-names>H</given-names></name><name><surname>Lester</surname> <given-names>T</given-names></name><name><surname>Izatt</surname> <given-names>L</given-names></name><name><surname>Lampe</surname> <given-names>AK</given-names></name><name><surname>Mohammed</surname> <given-names>SN</given-names></name><name><surname>Stewart</surname> <given-names>FJ</given-names></name><name><surname>Verloes</surname> <given-names>A</given-names></name><name><surname>Wilson</surname> <given-names>LC</given-names></name><name><surname>Healy</surname> <given-names>C</given-names></name><name><surname>Sharpe</surname> <given-names>PT</given-names></name><name><surname>Hammond</surname> <given-names>P</given-names></name><name><surname>Hughes</surname> <given-names>J</given-names></name><name><surname>Taylor</surname> <given-names>S</given-names></name><name><surname>Johnson</surname> <given-names>D</given-names></name><name><surname>Wall</surname> <given-names>SA</given-names></name><name><surname>Mavrothalassitis</surname> <given-names>G</given-names></name><name><surname>Wilkie</surname> <given-names>AOM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Reduced dosage of ERF causes complex craniosynostosis in humans and mice and links ERK1/2 signaling to regulation of osteogenesis</article-title><source>Nature Genetics</source><volume>45</volume><fpage>308</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1038/ng.2539</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twigg</surname> <given-names>SRF</given-names></name><name><surname>Hufnagel</surname> <given-names>RB</given-names></name><name><surname>Miller</surname> <given-names>KA</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>McGowan</surname> <given-names>SJ</given-names></name><name><surname>Taylor</surname> <given-names>J</given-names></name><name><surname>Craft</surname> <given-names>J</given-names></name><name><surname>Taylor</surname> <given-names>JC</given-names></name><name><surname>Santoro</surname> <given-names>SL</given-names></name><name><surname>Huang</surname> <given-names>T</given-names></name><name><surname>Hopkin</surname> <given-names>RJ</given-names></name><name><surname>Brady</surname> <given-names>AF</given-names></name><name><surname>Clayton-Smith</surname> <given-names>J</given-names></name><name><surname>Clericuzio</surname> <given-names>CL</given-names></name><name><surname>Grange</surname> <given-names>DK</given-names></name><name><surname>Groesser</surname> <given-names>L</given-names></name><name><surname>Hafner</surname> <given-names>C</given-names></name><name><surname>Horn</surname> <given-names>D</given-names></name><name><surname>Temple</surname> <given-names>IK</given-names></name><name><surname>Dobyns</surname> <given-names>WB</given-names></name><name><surname>Curry</surname> <given-names>CJ</given-names></name><name><surname>Jones</surname> <given-names>MC</given-names></name><name><surname>Wilkie</surname> <given-names>AOM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A recurrent mosaic mutation in SMO, encoding the hedgehog signal transducer smoothened, is the major cause of Curry-Jones syndrome</article-title><source>The American Journal of Human Genetics</source><volume>98</volume><fpage>1256</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2016.04.007</pub-id><pub-id pub-id-type="pmid">27236920</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twigg</surname> <given-names>SR</given-names></name><name><surname>Wilkie</surname> <given-names>AO</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A Genetic-Pathophysiological framework for craniosynostosis</article-title><source>The American Journal of Human Genetics</source><volume>97</volume><fpage>359</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2015.07.006</pub-id><pub-id pub-id-type="pmid">26340332</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullah</surname> <given-names>A</given-names></name><name><surname>Umair</surname> <given-names>M</given-names></name><name><surname>Majeed</surname> <given-names>AI</given-names></name><name><surname>Abdullah</surname></name> <name><surname>Jan</surname> <given-names>A</given-names></name><name><surname>Ahmad</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A novel homozygous sequence variant in <italic>GLI1</italic> underlies first case of autosomal recessive pre-axial polydactyly</article-title><source>Clinical Genetics</source><volume>95</volume><fpage>540</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1111/cge.13495</pub-id><pub-id pub-id-type="pmid">30620395</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veistinen</surname> <given-names>L</given-names></name><name><surname>Aberg</surname> <given-names>T</given-names></name><name><surname>Rice</surname> <given-names>DP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Convergent signalling through Fgfr2 regulates divergent craniofacial morphogenesis</article-title><source>Journal of Experimental Zoology Part B: Molecular and Developmental Evolution</source><volume>312B</volume><fpage>351</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1002/jez.b.21276</pub-id><pub-id pub-id-type="pmid">19205045</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veistinen</surname> <given-names>L</given-names></name><name><surname>Takatalo</surname> <given-names>M</given-names></name><name><surname>Tanimoto</surname> <given-names>Y</given-names></name><name><surname>Kesper</surname> <given-names>DA</given-names></name><name><surname>Vortkamp</surname> <given-names>A</given-names></name><name><surname>Rice</surname> <given-names>DP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Loss-of-Function of Gli3 in mice causes abnormal frontal bone morphology and premature synostosis of the interfrontal suture</article-title><source>Frontiers in Physiology</source><volume>3</volume><elocation-id>121</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2012.00121</pub-id><pub-id pub-id-type="pmid">22563320</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veistinen</surname> <given-names>LK</given-names></name><name><surname>Mustonen</surname> <given-names>T</given-names></name><name><surname>Hasan</surname> <given-names>MR</given-names></name><name><surname>Takatalo</surname> <given-names>M</given-names></name><name><surname>Kobayashi</surname> <given-names>Y</given-names></name><name><surname>Kesper</surname> <given-names>DA</given-names></name><name><surname>Vortkamp</surname> <given-names>A</given-names></name><name><surname>Rice</surname> <given-names>DP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Regulation of calvarial osteogenesis by concomitant De-repression of GLI3 and activation of IHH targets</article-title><source>Frontiers in Physiology</source><volume>8</volume><elocation-id>1036</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2017.01036</pub-id><pub-id pub-id-type="pmid">29311969</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vortkamp</surname> <given-names>A</given-names></name><name><surname>Gessler</surname> <given-names>M</given-names></name><name><surname>Grzeschik</surname> <given-names>KH</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>GLI3 zinc-finger gene interrupted by translocations in greig syndrome families</article-title><source>Nature</source><volume>352</volume><fpage>539</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1038/352539a0</pub-id><pub-id pub-id-type="pmid">1650914</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>M</given-names></name><name><surname>Uhlhorn</surname> <given-names>VL</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Peter</surname> <given-names>I</given-names></name><name><surname>Martinez-Abadias</surname> <given-names>N</given-names></name><name><surname>Hill</surname> <given-names>CA</given-names></name><name><surname>Percival</surname> <given-names>CJ</given-names></name><name><surname>Richtsmeier</surname> <given-names>JT</given-names></name><name><surname>Huso</surname> <given-names>DL</given-names></name><name><surname>Jabs</surname> <given-names>EW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Activation of p38 MAPK pathway in the skull abnormalities of apert syndrome Fgfr2(+P253R) mice</article-title><source>BMC Developmental Biology</source><volume>10</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.1186/1471-213X-10-22</pub-id><pub-id pub-id-type="pmid">20175913</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>X</given-names></name><name><surname>Oberoi</surname> <given-names>K</given-names></name><name><surname>Phelps</surname> <given-names>R</given-names></name><name><surname>Couwenhoven</surname> <given-names>R</given-names></name><name><surname>Sun</surname> <given-names>M</given-names></name><name><surname>Rezza</surname> <given-names>A</given-names></name><name><surname>Holmes</surname> <given-names>G</given-names></name><name><surname>Percival</surname> <given-names>CJ</given-names></name><name><surname>Friedenthal</surname> <given-names>J</given-names></name><name><surname>Krejci</surname> <given-names>P</given-names></name><name><surname>Richtsmeier</surname> <given-names>JT</given-names></name><name><surname>Huso</surname> <given-names>DL</given-names></name><name><surname>Rendl</surname> <given-names>M</given-names></name><name><surname>Jabs</surname> <given-names>EW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>p38 inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice</article-title><source>Journal of Clinical Investigation</source><volume>122</volume><fpage>2153</fpage><lpage>2164</lpage><pub-id pub-id-type="doi">10.1172/JCI62644</pub-id><pub-id pub-id-type="pmid">22585574</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkie</surname> <given-names>AOM</given-names></name><name><surname>Johnson</surname> <given-names>D</given-names></name><name><surname>Wall</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Clinical genetics of craniosynostosis</article-title><source>Current Opinion in Pediatrics</source><volume>29</volume><fpage>622</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1097/MOP.0000000000000542</pub-id><pub-id pub-id-type="pmid">28914635</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname> <given-names>WJ</given-names></name><name><surname>Cho</surname> <given-names>YD</given-names></name><name><surname>Kim</surname> <given-names>WJ</given-names></name><name><surname>Bae</surname> <given-names>HS</given-names></name><name><surname>Islam</surname> <given-names>R</given-names></name><name><surname>Woo</surname> <given-names>KM</given-names></name><name><surname>Baek</surname> <given-names>JH</given-names></name><name><surname>Bae</surname> <given-names>SC</given-names></name><name><surname>Ryoo</surname> <given-names>HM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Prolyl isomerase Pin1-mediated conformational change and subnuclear focal accumulation of Runx2 are crucial for fibroblast growth factor 2 (FGF2)-induced osteoblast differentiation</article-title><source>Journal of Biological Chemistry</source><volume>289</volume><fpage>8828</fpage><lpage>8838</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.516237</pub-id><pub-id pub-id-type="pmid">24509851</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>K</given-names></name><name><surname>Herr</surname> <given-names>AB</given-names></name><name><surname>Waksman</surname> <given-names>G</given-names></name><name><surname>Ornitz</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Loss of fibroblast growth factor receptor 2 ligand-binding specificity in apert syndrome</article-title><source>PNAS</source><volume>97</volume><fpage>14536</fpage><lpage>14541</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.26.14536</pub-id><pub-id pub-id-type="pmid">11121055</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zerial</surname> <given-names>M</given-names></name><name><surname>McBride</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Rab proteins as membrane organizers</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>2</volume><fpage>107</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1038/35052055</pub-id><pub-id pub-id-type="pmid">11252952</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>H</given-names></name><name><surname>Feng</surname> <given-names>J</given-names></name><name><surname>Ho</surname> <given-names>TV</given-names></name><name><surname>Grimes</surname> <given-names>W</given-names></name><name><surname>Urata</surname> <given-names>M</given-names></name><name><surname>Chai</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The suture provides a niche for mesenchymal stem cells of craniofacial bones</article-title><source>Nature Cell Biology</source><volume>17</volume><fpage>386</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1038/ncb3139</pub-id><pub-id pub-id-type="pmid">25799059</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.55829.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Reviewing Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Hatch</surname><given-names>Nan</given-names> </name><role>Reviewer</role><aff><institution/></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The authors have effectively determined the mechanism underlying craniosynostosis caused by <italic>Rab23</italic> deletion and determined the function of RAB23 during intramembranous bone formation. Notably, RAB23 coordinates skull morphogenesis by regulating suture patency through FGF10-ERK1/2RUNX2 signaling, repressing <italic>Hh</italic> targets through a canonical pathway, and regulating the sutural stem cell marker GLI1.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;RAB23 coordinates early osteogenesis by repressing FGF10-pERK1/2-RUNX2 and GLI1&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Mone Zaidi as the Reviewing Editor and Clifford Rosen as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Nan Hatch (Reviewer #1).</p><p>The reviewers have discussed the reviews with one another, and on basis of their recommendation, we are requesting a revised submission. In recognition of the fact that revisions may take longer than the two months we typically allow due to the COVID-19 pandemic, until the research enterprise restarts in full, we will give authors as much time as they need to submit revised manuscripts.</p><p>Summary:</p><p>The authors have generated and studied global <italic>Rab23</italic><sup>-/-</sup> mice at embryonic time points to establish an essential role for <italic>Rab23</italic> in skull growth and morphogenesis. These mice serve as a useful model for Carpenter Syndrome, features of which include craniosyntososis and dactyly. The current work address mechanism by integrating studies of developmental anatomy, gene expression, analysis of cell proliferation and pharmacological inhibition. While there was overall interest in the manuscript and its conclusions, significant concerns were raised regarding the approach, specifically arising from the absence of conclusive experiments.</p><p>Essential revisions:</p><p>1) The authors do not take a cell biological approach to dissect the primary chain of events leading to the phenotypes they observe. Furthermore, the experimental results are based on collections of what are undoubtedly highly heterogeneous cell types, namely whole calvaria, cultured calvaria-derived mesenchymal cells, dissected and cultured lambdoid sutures, making it impossible to distinguish primary from secondary events in the chain of pathophysiology. This aspect needs clarification.</p><p>2) Stronger rationale should be provided earlier in the manuscript explaining why FGF10 and PITX2 were the genes chosen to study the differentially expressed genes. The same could be said for <italic>Hh</italic> and GLI1 expression. The manuscript would benefit from cluing in the reader earlier on regarding rationale for studying these specific factors in their study. Additionally, there is review concern that there is no other evidence for the direct regulation of these molecules by RAB23, and given the caveats above (point 1), secondary mechanisms for these effects are entirely possible. This aspect needs clarification. Furthermore, there is a paucity of robust evidence of the functional significance of any of these molecules in suture fusion. Changed expression levels of any given gene does not necessarily establish its role in a phenotype. The authors should examine in loss- or gain-of-function experiments the functionality of what they consider as the most critical disease-causing gene or gene set.</p><p>3) The authors checked premature suture fusion either by CT scanning or alizarin red-alzarin blue staining. Histological analysis, or at least coronal/sagittal sections of the suture CT images, are necessary to confirm the suture fusion. Furthermore, they need to co-stain markers, such as ALP and RUNX2, with their RNAscope analyses (e.g. Figure 1P, middle panel) and immunofluorescence staining images. It is currently difficult to differentiate the suture mesenchyme from the bone at these embryonic stages, which makes data interpretation difficult. Finally, to provide evidence for their conclusion that <italic>Rab23</italic> lambdoid suture and MEF cells show increased osteoprogenitor cell proliferation, the authors must to co-localize Edu with osteoprogenitor cell markers in vivo, noting that Edu will label all proliferating cells.</p><p>4) There is no supporting data for a downstream action of FGF10 although both FGF10 and PITX2 are increased in <italic>Rab23</italic><sup>-/-</sup> mice. The authors have only validated the in situ expression of <italic>Pitx2</italic>, not of <italic>Fgf10</italic>. There is published data showing that PITX2 is an upstream regulator of FGF10 during early organogenesis of other tissues. Data showing that FGF10 is downstream of PITX2 in suture development is therefore required to strengthen the conclusion.</p><p>5) The authors noted an elevated expression of FGF10 and FGFR1b in <italic>Rab23</italic><sup>-/-</sup> mice, and concluded that increased FGFR1b was induced by FGF10. There is however the possibility that increased FGFR1b is a direct result of the <italic>Rab23</italic> mutation. This possibility needs to be discussed or excluded experimentally.</p><p>6) The authors found elevated pERK1/2, RUNX2, <italic>Hh</italic> and GLI1, as well as decreased p38 in <italic>Rab23</italic><sup>-/-</sup> mice. It however remains unclear whether the elevated pERK1/2 and pp38 are secondary to FGF signaling, and whether <italic>Hh</italic> and GLI1 upregulation is caused by phosphorylation of ERK1/2. Interestingly, published data shows that RAB23 can negatively regulate the <italic>Hh</italic> pathway directly. Therefore, it is critical to experimentally establish a direct role for RAB23 in changing gene expression. Promoter-reporter assays could be useful in this regard.</p><p>7) The authors used pSmad1/5/8 to test whether the TGF-β superfamily was affected by the <italic>Rab23</italic> mutation. Since pSmad1/5/8 is the readout of global BMP signaling, another readout of the TGF signaling pathway, pSmad2/3, should be tested.</p><p>8) It is surprising that the epithelial, but not mesenchymal splice forms of FGFR1 are upregulated in suture and/or calvarial tissue. The authors should make some attempt to explain as to how or why this is the case if the sample should only contain mesenchymal cells.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.55829.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The authors do not take a cell biological approach to dissect the primary chain of events leading to the phenotypes they observe. Furthermore, the experimental results are based on collections of what are undoubtedly highly heterogeneous cell types, namely whole calvaria, cultured calvaria-derived mesenchymal cells, dissected and cultured lambdoid sutures, making it impossible to distinguish primary from secondary events in the chain of pathophysiology. This aspect needs clarification.</p></disp-quote><p>We thank the reviewers for bringing up this point. We agree that to understand the primary role of RAB23 direct cell biological investigations are needed. Although the direct cellular roles of most RABs are known, very little is understood about RAB23, i.e., role in endocytosis, vesicle formation, recycling and degradation. We agree that by using immortalized cells one can use a standardized approach in which it is easier to understand the effects of a specific intervention. We have added text to the manuscript to acknowledge and clarify these aspects.</p><p>It is true that suture morphogenesis and aberrant suture fusion can be investigated by cell biological approach. However, these developmental events are complex and a multiple-pronged strategy is also useful.</p><p>By not using such an approach you may bypass the real-time developmental events where multiple regulatory signaling pathways are highly orchestrated. These events regulate not only cell differentiation and function but also regulate tissue-tissue interactions, morphogenesis, patterning, boundary formation within the developing calvaria (Helms et al., 2005) (Twigg and Wilkie, 2015).</p><p>As the reviewers mentioned in this study we have combined many approaches (analysis of whole calvaria, cultured calvaria-derived mesenchymal cells, in vitro culture of dissected lambdoid sutures). It is true that some cellular heterogeneity may exist in the calvaria-derived mesenchymal cell cultures but during processing and after enzymatic digestion, epithelial cells, meningeal cells and cartilage cells are lost. Indeed this is a very well investigated, standard technique to harvest osteoblast progenitors (Lana-Elola et al., 2007; Liu et al., 2019; Malaval et al., 1999; Rodan and Noda, 1991)</p><p>We believe that by analyzing intact tissues and isolated cells we have provided a broad view of suture fusion in which location-specific information is maintained. Nevertheless, we do acknowledge that further analysis using a more cell biological approach will help in deciphering the role of RAB23, specifically during endocytosis.</p><disp-quote content-type="editor-comment"><p>2) Stronger rationale should be provided earlier in the manuscript explaining why FGF10 and PITX2 were the genes chosen to study the differentially expressed genes. The same could be said for Hh and GLI1 expression. The manuscript would benefit from cluing in the reader earlier on regarding rationale for studying these specific factors in their study. Additionally, there is review concern that there is no other evidence for the direct regulation of these molecules by RAB23, and given the caveats above (point 1), secondary mechanisms for these effects are entirely possible. This aspect needs clarification. Furthermore, there is a paucity of robust evidence of the functional significance of any of these molecules in suture fusion. Changed expression levels of any given gene does not necessarily establish its role in a phenotype. The authors should examine in loss- or gain-of-function experiments the functionality of what they consider as the most critical disease-causing gene or gene set.</p></disp-quote><p>We thank the reviewers for these comments. Stronger rationale for why FGF signaling in particular, <italic>Fgf10</italic> and <italic>Pitx2</italic> were chosen to study further is now given early in the manuscript both in the Introduction section and in the Results section.</p><p>Most forms of syndromic craniosynostoses are caused by gain-of-function mutations in FGFR where the receptors exhibit ligand independent activation or lost the ligand binding specificity and bind with cognate ligand (Hajihosseini et al., 2009; Ibrahimi et al., 2001; Ibrahimi et al., 2004; Johnson and Wilkie, 2011; Yu et al., 2000). FGFRs isoforms show distinct FGF ligand binding affinity and biological functions. However, studies have shown that in Apert syndrome (FGFR2 mutation) mouse model FGFR2 isoform FGFR2c loses ligand specificity, and able to bind with cognate FGF10 (Hajihosseini et al., 2009; Ibrahimi et al., 2001; Ibrahimi et al., 2004; Johnson and Wilkie, 2011; Yu et al., 2000). Interestingly, genetic knockdown of <italic>Fgf10</italic> in this FGFR2 mutant mouse can rescue the premature suture fusion (Hajihosseini et al., 2009). FGF signaling pathway members have not been linked to RAB23-mediated trafficking. However, a study suggests that RAB23 resides in the plasma membrane and it is proposed to be involved in endocytosis (Evans et al., 2003). It has been shown that RAB23 transports dopamine receptors to the primary cilium (Leaf and Von Zastrow, 2015) and in this context, RAB23 might be involved in ligand-receptor turnover.</p><p>It was first evident that RAB23 is a negative regulator of hedgehog (<italic>Hh</italic>) signaling in mouse neural tube development (Eggenschwiler et al., 2001) and further studies showed that RAB23 negatively regulates GLI1 in Su(Fu) dependant manner in which RAB23 expression reduces nuclear localization of <italic>Gli1</italic> transcription factor (Chi et al., 2012). <italic>Gli1</italic> positive cells have been identified in the suture as the main source of mesenchymal stem cells and <italic>Gli1</italic> plays critical role in maintaining suture patency (Zhao et al., 2015). The above mentioned findings collectively encouraged us to unveil the role of RAB23 in regulating <italic>Hh</italic> and <italic>Gli1</italic> in suture biology.</p><p>We highly agree with the reviewers that secondary mechanisms for these effects are possible. To understand such effects, we have performed new experiments and the findings are presented in Figure 6 (Figure 6E-H) where we show that inhibition of hedgehog transducer SMO by cyclopamine could not alter pERK1/2, rather inhibition of pERK1/2 could downregulate GLI1. Primary effects of RAB23 acting as a small GTP-ase during vesicle trafficking may regulate the turnover of FGFR and thereby FGF signaling, but there is no direct evidence for this. We have clarified this in the manuscript. The Figure 6E-H is incorporated in revised manuscript along with previously shown Figure 6A-D.</p><p>We agree that there is little robust evidence for the fundamental significance of <italic>Fgf10</italic> and <italic>Pitx2</italic>. These, however, good evidence that FGF signaling, in general, is involved in suture fusion and are good evidence for the involvement of <italic>Hh</italic> signaling via <italic>Gli1</italic>. Mutation in several <italic>Hh</italic> pathway members including <italic>Gli1</italic> result in premature suture fusion (Twigg et al., 2016; Zhao et al., 2015).</p><p>We thank reviewer for suggesting us to examine loss- or gain-of-function experiments the functionality of what could be the most critical disease causing gene or gene set. We have performed additional experiments to understand this, our findings are presented in new figures (Figure 6E-H, Figure 3H, Figure 1P-c and Figure 4A-B). All these figures now incorporated in revised manuscript. Here we showed that abrogation of GLI1 and pERK1/2 by combined action of cyclopamine and U0126, and cyclopamine alone indicates that RUNX2 is the most critical gene that lies downstream of both pERK1/2 and GLI1 (Figure 6E-H). Co-staining of RAB23 and RUNX2 (Figure 1P-c) showed overlapped expression in the osteogenic front where the EdU positive cells are more prominent. Interestingly, EdU positive cells also showed overlapped signals with RUNX2 in the osteogenic front (Figure 4A-B). In addition, we showed that stimulation of RAB23 deficient cells by FGF10, overexpressed RUNX2 expression (Figure 3H). Here, we shown two ways of RUNX2 regulation: (1) overactivating the FGFR signaling and by (2) abrogating the pERK1/2 signaling. Our lab previously shown that RUNX2 is a downstream candidate of <italic>Hh</italic> signaling and critical regulator of suture patency and therefore, loss of one allele of RUNX2 in overactivation <italic>Hh</italic> signaling mouse model of craniosynostosis rescued from premature suture fusion (Tanimoto et al., 2012). Current study thus showed well synergies and drawn the network of RAB23, FGFR, <italic>Hh</italic> and RUNX2 signaling in suture biology.</p><disp-quote content-type="editor-comment"><p>3) The authors checked premature suture fusion either by CT scanning or alizarin red-alzarin blue staining. Histological analysis, or at least coronal/sagittal sections of the suture CT images, are necessary to confirm the suture fusion. Furthermore, they need to co-stain markers, such as ALP and RUNX2, with their RNAscope analyses (e.g. Figure 1P, middle panel) and immunofluorescence staining images. It is currently difficult to differentiate the suture mesenchyme from the bone at these embryonic stages, which makes data interpretation difficult. Finally, to provide evidence for their conclusion that Rab23 lambdoid suture and MEF cells show increased osteoprogenitor cell proliferation, the authors must to co-localize Edu with osteoprogenitor cell markers in vivo, noting that Edu will label all proliferating cells.</p></disp-quote><p>We thank the reviewers for pointing out these important issues.</p><p>We have now provided a new figure, which confirms of coronal suture fusion in a micro-CT slice /section through the <italic>Rab23</italic><sup>-/-</sup> calvaria. We now incorporated this image into Figure 1 (Figure 1B-b, green arrow) in the revised manuscript.</p><p>In response to the co-stain marker issue, new immunohistochemical staining with RAB23 and RUNX2 has been carried out in Wt sections. Figure 1P-c shows RAB23 expression in the lambdoid suture (green) with RUNX2 co-stain marker (red). The figure shows RAB23 is expressed in the osteogenic front and RUNX2 is co-localized with RAB23 (yellow). The Figure 1P-c is incorporated in revised manuscript along with previously shown Rab23 RNAscope expression Figure 1P-b.</p><p>In response to whether the osteoprogenitor cells are proliferating we have now performed a RUNX2 immunohistochemistry on EdU-pulsed tissue sections (Wt and Rab23<sup>-/-</sup>). The new figure (Figure 4A-B) shows EdU-pulsed proliferating cells (red) in the Wt and Rab23 deficient sutures (E17.5) stained with osteoprogenitor marker RUNX2 (green). RUNX2 is co-localizes with EdU in the osteogenic front (yellow, white arrows) in both Wt and RAB23 deficient samples. The Figure 4A-B is incorporated in revised manuscript along with previously shown Figure 4C-J.</p><disp-quote content-type="editor-comment"><p>4) There is no supporting data for a downstream action of FGF10 although both FGF10 and PITX2 are increased in Rab23<sup>-/-</sup> mice. The authors have only validated the in situ expression of Pitx2, not of Fgf10. There is published data showing that PITX2 is an upstream regulator of FGF10 during early organogenesis of other tissues. Data showing that FGF10 is downstream of PITX2 in suture development is therefore required to strengthen the conclusion.</p></disp-quote><p>We highly appreciate reviewers’ comments. Here a new figure (Figure 3H) added which indicating downstream action of FGF10. When RAB23 deficient cells were treated with or without FGF10 (500 ng/ml) for 2 and 4 hours followed by RT-qPCR analysis revealed FGF10 stimulation upregulates <italic>Runx2</italic> expression in both time points, indicating that <italic>Runx2</italic> is a downstream target of FGF10 signaling. The Figure 3H is incorporated in revised manuscript along with previously shown Figure 3.</p><p>In addition, we have now acknowledged in the manuscript text that we have not shown <italic>Pitx2</italic> regulation of FGF10 in the calvaria. Also, we downplayed this aspect by removing <italic>Pitx2</italic> from the schematic diagram (Figure 7). Hopefully, this improves the focus and clarifies the manuscript.</p><disp-quote content-type="editor-comment"><p>5) The authors noted an elevated expression of FGF10 and FGFR1b in Rab23<sup>-/-</sup> mice, and concluded that increased FGFR1b was induced by FGF10. There is however the possibility that increased FGFR1b is a direct result of the Rab23 mutation. This possibility needs to be discussed or excluded experimentally.</p></disp-quote><p>This is a good point. We agree with the possibility that RAB23 could directly regulate FGFR1b. RAB23 is localized to the plasma membrane and are proposed to be involved in endocytosis and growth factor receptor recycling and turnover, and therefore, availability for ligand binding at the cell surface (Evans et al., 2003). This issue is now discussed in the Introduction and Discussion.</p><disp-quote content-type="editor-comment"><p>6) The authors found elevated pERK1/2, RUNX2, Hh and GLI1, as well as decreased p38 in Rab23<sup>-/-</sup> mice. It however remains unclear whether the elevated pERK1/2 and pp38 are secondary to FGF signaling, and whether Hh and GLI1 upregulation is caused by phosphorylation of ERK1/2. Interestingly, published data shows that RAB23 can negatively regulate the Hh pathway directly. Therefore, it is critical to experimentally establish a direct role for RAB23 in changing gene expression. Promoter-reporter assays could be useful in this regard.</p></disp-quote><p>We appreciate this point. We agree that these aspects should be clarified. To test whether GLI1 upregulation is caused by phosphorylation of ERK1/2 alone, we used the SMO inhibitor cyclopamine to block canonical <italic>Hh</italic> signaling and also U0126 to block ERK1/2 (Individually and in combination with cyclopamine) in <italic>Rab23</italic><sup>-/-</sup> cells. New Figure 6A-H shows that U0126 and cyclopamine both individually can downregulate GLI1. This indicates that GLI1 is regulated through both canonical <italic>Hh</italic> signaling and also indirectly through pERK1/2. Cyclopamine did not downregulate pERK1/2, indicating that GLI1 resides downstream of pERK1/2.</p><p>The reviewers state that published data shows that RAB23 can negatively regulate the <italic>Hh</italic> pathway directly. Therefore, it is logical that the increased level of GLI1 in RAB23 mutant cells can in part be corrected by blocking canonical <italic>Hh</italic> signaling. Our investigation further unveiled that RUNX2 is downstream of both pERK1/2 and GLI1 (Figure 6E-H). These experiments combined with the data from Figures 2 and 3 establish a role for RAB23 in changing gene expression of FGF/MAPK signaling, <italic>Hh</italic>/GLI1 signaling and the osteoblast master regulator RUNX2. This data is also consistent with the findings that GTP bound block form of RAB23 reduces nuclear localization of GLI1 in hepatocellular carcinoma cell lines (Sun et al., 2012).</p><p>The Figure 6E-H is incorporated in revised manuscript along with previously shown Figure 6A-D.</p><disp-quote content-type="editor-comment"><p>7) The authors used pSmad1/5/8 to test whether the TGF-β superfamily was affected by the Rab23 mutation. Since pSmad1/5/8 is the readout of global BMP signaling, another readout of the TGF signaling pathway, pSmad2/3, should be tested.</p></disp-quote><p>This is an excellent point. We now provide new additional information in figure (Figure 3—figure supplement 1C-D) that pSMAD2/3 along with pSMAD1/5/8 are not differentially expressed in Wt and RAB23 deficient sutures. This figure is now updated in revised manuscript.</p><disp-quote content-type="editor-comment"><p>8) It is surprising that the epithelial, but not mesenchymal splice forms of FGFR1 are upregulated in suture and/or calvarial tissue. The authors should make some attempt to explain as to how or why this is the case if the sample should only contain mesenchymal cells.</p></disp-quote><p>We agree that it is surprising that the FGFR1b splice form, which is normally expressed in epithelia, is upregulated in the mesenchymal suture. However, this is not without precedent. While FGFRc isoforms are predominantly expresses in the mesenchyme and b isoforms in the epithelium, their expression is not mutually exclusive and FGFR1b is known to be expressed by late embryonic murine lung mesenchymal cells and also in the zebrafish in the sutural mesenchyme (Al Alam et al., 2015; Rice et al., 2003; Rice et al., 2004; Topczewska et al., 2016). Under pathological/force conditions mis-expression of splice forms can occur. Occasionally, Apert craniosynostosis syndrome is caused by heterozygous Alu-insertions or large deletions in the FGFR2c domalin. These rare mutations induce abnormal expression of the FGFR2b splice form alongside FGFR2c splice form in mesenchymal cells. This permits cells to respond to both b- and c-activating FGF ligands including FGF10 (Bochukova et al., 2009; Oldridge et al., 1999).</p><p>We have changed the manuscript text to elaborate on this surprising finding.</p><p>References:Fuller, K., O'Connell, J. T., Gordon, J., Mauti, O., and Eggenschwiler, J. (2014). Rab23 Helms, J. A., Cordero, D., and Tapadia, M. D. (2005). New insights into craniofacial morphogenesis. Development (Cambridge, England), 132(5), 851-861. doi:132/5/851 [pii]Leaf, A., and Von Zastrow, M. (2015). Dopamine receptors reveal an essential role of IFT-B, KIF17, and Rab23 in delivering specific receptors to primary cilia. <italic>eLife, 4</italic>, 10.7554/<italic>eLife</italic>.06996. doi:10.7554/<italic>eLife</italic>.06996 [doi]Liu, B., Lu, Y., Wang, Y., Ge, L., Zhai, N., and Han, J. (2019). A protocol for isolation and identification and comparative characterization of primary osteoblasts from mouse and rat calvaria. Cell and Tissue Banking, 20(2), 173-182. doi:10.1007/s10561-019-09751-0 [doi]Malaval, L., Liu, F., Roche, P., and Aubin, J. E. (1999). Kinetics of osteoprogenitor proliferation and osteoblast differentiation in vitro. Journal of Cellular Biochemistry, 74(4), 616-627. doi:10.1002/(SICI)1097-4644(19990915)74:43.0.CO;2-Q [pii]Sun, H. J., Liu, Y. J., Li, N., Sun, Z. Y., Zhao, H. W., Wang, C.,... Huang, S. H. (2012). Sublocalization of Rab23, a mediator of sonic hedgehog signaling pathway, in hepatocellular carcinoma cell lines. Molecular Medicine Reports, 6(6), 1276-1280. doi:10.3892/mmr.2012.1094 [doi]Tanimoto, Y., Veistinen, L., Alakurtti, K., Takatalo, M., and Rice, D. P. (2012). Prevention of premature fusion of calvarial suture in GLI-kruppel family member 3 (Gli3)-deficient mice by removing one allele of runt-related transcription factor 2 (Runx2). The Journal of Biological Chemistry, 287(25), 21429-21438. doi:10.1074/jbc.M112.362145 [doi]</p></body></sub-article></article>